Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.59 |
| ▸ | AGXT | P21549 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 7/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34413 | 0.88 | IDO1 (0.67) | IDO1AGXTCA1CA2APP | |
| Potassium SCHEMBL1477050 | 0.86 | IDO1 (0.64) | IDO1AGXTCA1CA2APP | |
| SCHEMBL1475481 | 0.86 | IDO1 (0.64) | IDO1AGXTCA1CA2APP | |
| SCHEMBL15112891 | 0.85 | IDO1 (0.48) | IDO1AGXTCA1CA2APP | |
| SCHEMBL8499580 | 0.84 | IDO1 (0.61) | IDO1AGXTCA1CA2APP | |
| SCHEMBL4259905 | 0.84 | IDO1 (0.52) | IDO1AGXTCA1CA2APP | |
| SCHEMBL11132718 | 0.82 | IDO1 (0.59) | IDO1AGXTCA1CA2APP | |
| SCHEMBL11132720 | 0.82 | LTA4H (0.65) | IDO1AGXTCA1CA2APP | |
| SCHEMBL2618879 | 0.82 | IDO1 (0.59) | IDO1AGXTCA1CA2APP | |
| SCHEMBL4259907 | 0.81 | CA1 (0.49) | IDO1AGXTCA1CA2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1028 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899238-A | Condensed-cyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-04-29 | — | — | CN | claimed |
| WO-2025053792-A1 | COLLECTIVE SYNTHESIS OF PHANTOMOLIN FAMILY THROUGH TOTAL SYNTHESIS OF THE SESQUITERPENE LACTONE MOLEPHANTIN | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | claimed |
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-02-16 | — | — | US | claimed |
| WO-2021216722-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2021-10-28 | — | — | WO | claimed |
| US-10662202-B2 | Synthesis of cephalosporin compounds | MERCK SHARP & DOHM CORP. (US) | 2020-05-26 | — | — | US | claimed |
| US-10632099-B2 | Non-aromatic difluoro analogues of resorcylic acid lactones | UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2020-04-28 | — | — | US | claimed |
| EP-2776382-B1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2018-09-19 | — | — | EP | claimed |
| US-20180153854-A1 | NON-AROMATIC DIFLUORO ANALOGUES OF RESORCYLIC ACID LACTONES | NORTH CAROLINA AT GREENSBORO, UNIVERSITY OF | 2018-06-07 | — | — | US | claimed |
| EP-2308861-B1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI R&D MAN CO LTD (JP) | 2017-03-01 | — | — | EP | claimed |
| WO-2016196256-A2 | NON-AROMATIC DIFLUORO ANALOGUES OF RESORCYLIC ACID LACTONES | UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2016-12-08 | — | — | WO | claimed |
| US-20160185717-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2016-06-30 | — | — | US | claimed |
| CN-104876904-A | Macrocyclic Compounds Useful As Pharmaceuticals | EISAI R&D MAN CO LTD | 2015-09-02 | — | — | CN | claimed |
| EP-2427057-B1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN KETTERING INST CANCER (US) | 2015-08-12 | — | — | EP | claimed |
| CN-104725628-A | Single functional branched polyethylene glycol containing degradable radical, preparation method and biorelevant substance of single functional branched polyethylene glycol | XIAMEN SINOPEG BIOTECH CO LTD | 2015-06-24 | — | — | CN | claimed |
| CN-104530415-A | Hetero-functionalized Y-type polyethylene glycol derivative, preparation method and biologically related substance thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104530417-A | Multifunctional H-type polyethylene glycol derivative and preparation method thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| EP-2821394-A1 | Compounds with antibacterial activity | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2015-01-07 | — | — | EP | claimed |
| US-8193270-B2 | Method of making composites and nanocomposites | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-06-05 | — | — | US | claimed |
| US-7915306-B2 | For therapy of inflammatory or autoimmune disorders | EISAI CO., LTD. (JP) | 2011-03-29 | — | — | US | claimed |
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | CITY OF HOPE (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4691557-A2 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | Madrigal Pharmaceuticals, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250381161-A1 | COMPOSITIONS AND METHODS FOR TREATING HEARING AND OCULAR DISORDERS | ANIDA PHARMA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4658315-A1 | POLYMER-DRUG CONJUGATES | Primelink Biotherapeutics (Shenzhen) Co., Ltd. (CN) | 2025-12-10 | — | — | EP | disclosed |
| US-12492180-B2 | Process and intermediates for the preparation of Voxelotor | CURIA SPAIN, S.A.U. (ES) | 2025-12-09 | — | — | US | disclosed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-20250205356-A1 | POLYMER-DRUG CONJUGATES | PRIMELINK BIOTHERAPEUTICS (SHENZHEN) CO., LTD (CN) | 2025-06-26 | — | — | US | disclosed |
| WO-2025124531-A1 | 1, 3-BENZODIOXOL DERIVATIVES AND USES THEREOF | GEWU BIO CO., LTD (CN) | 2025-06-19 | — | — | WO | disclosed |
| CN-113784721-B | High activity compounds against COVID-19 | 阿堤亚制药公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119899238-A | Condensed-cyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-111330016-B | Antibody Drug Conjugates (ADCs) that bind 158P1D7 protein | 艾更斯司股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | AGENSYS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4523681-A1 | AMORPHOUS SOLID SUCCINYLATED 3-(FATTY ACID AMIDO)-2-HYDROXY-1-(PROTECTED HYDROXY)-PROPANE SALTS AND METHODS OF MAKING THE SAME | Geron Corporation (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025053792-A1 | COLLECTIVE SYNTHESIS OF PHANTOMOLIN FAMILY THROUGH TOTAL SYNTHESIS OF THE SESQUITERPENE LACTONE MOLEPHANTIN | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | disclosed |
| EP-4496823-A1 | POLYMER-DRUG CONJUGATES | Primelink Biotherapeutics (Shenzhen) Co., Ltd (CN) | 2025-01-29 | — | — | EP | disclosed |
| EP-3581206-B1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE P13K-AKT MTOR PATHWAY | SEAGEN INC (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-119139338-A | High activity compounds against COVID-19 | 阿堤亚制药公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-4051242-B1 | AMORPHOUS SOLID SUCCINYLATED 3-(FATTY ACID AMIDO)-2-HYDROXY-1-(PROTECTED HYDROXY)-PROPANE SALTS AND METHODS OF MAKING THE SAME | GERON CORP (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-111330017-B | Antibody Drug Conjugates (ADCs) that bind 158P1D7 protein | 艾更斯司股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240382611-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-118948877-A | High activity compounds against COVID-19 | 阿堤亚制药公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240360074-A1 | Crystalline Solids of 3-Palmitoyl-Amido-1,2-Propanediol and 3-Palmitoyl-Amido-2-Hydroxy-1-Dimethoxytriphenylmethylether-Propane and Methods of Making and Using the Same | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2024-10-31 | — | — | US | disclosed |
| US-12122735-B2 | Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1- (protected hydroxy)-propane salts and methods of making the same | GERON CORPORATION (US) | 2024-10-22 | — | — | US | disclosed |
| CN-113429559-B | Six-arm polyethylene glycol derivative with terminal iso-functionalization and preparation method thereof | 厦门赛诺邦格生物科技股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240261316-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. | 2024-08-08 | — | — | US | disclosed |
| WO-2024160204-A1 | POLYMER-OLIGONUCLEOTIDE CONJUGATES | PRIMELINK BIOTHERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024160202-A1 | POLYMER-DRUG CONJUGATES | PRIMELINK BIOTHERAPEUTICS (SHENZHEN) CO., LTD. (CN) | 2024-08-08 | — | — | WO | disclosed |
| EP-4406594-A2 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | Madrigal Pharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-113677364-B | Pharmaceutical compositions comprising anti-191P 4D12 antibody drug conjugates and methods of use thereof | 艾更斯司股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-112694608-B | Six-arm polyethylene glycol derivative, preparation method and modified biological related substance | 厦门赛诺邦格生物科技股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) | 2024-06-11 | — | — | US | disclosed |
| CN-115010915-B | Nitrogen-branched nine-arm polyethylene glycol derivative, preparation method and modified biologically-relevant substance thereof | 厦门赛诺邦格生物科技股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-113365992-B | Process and intermediates for the preparation of Wo Sailuo torr | 晶体制药独资有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11987540-B2 | Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same | GERON CORPORATION (US) | 2024-05-21 | — | — | US | disclosed |
| US-11986481-B2 | Method of synthesizing thyroid hormone analogs and polymorphs thereof | MADRIGAL PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240148742-A1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | MADRIGAL PHARMACEUTICALS, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4023641-B1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | MADRIGAL PHARMACEUTICALS INC (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024083861-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | SELABTEC SCIENCES, SLU (ES) | 2024-04-25 | — | — | WO | disclosed |
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEAGEN INC (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4356909-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | Selabtec Sciences, SLU (ES) | 2024-04-24 | — | — | EP | disclosed |
| US-11964025-B2 | Peptide-containing linkers for antibody-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240122936-A1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2024-04-18 | — | — | US | disclosed |
| US-20240116856-A1 | NOVEL CAPSAICIN ANALOGS AND USES THEREOF | YOUNG BIOPHARMA, LLC | 2024-04-11 | — | — | US | disclosed |
| WO-2024074604-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | INSTITUTO BIOMAR, S.A (ES) | 2024-04-11 | — | — | WO | disclosed |
| EP-4349409-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | Instituto Biomar S.A. (ES) | 2024-04-10 | — | — | EP | disclosed |
| US-20240043556-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| WO-2023250031-A1 | COMPOSITIONS AND METHODS FOR TREATING HEARING AND OCULAR DISORDERS | ANIDA PHARMA INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-3645548-B1 | METHODS FOR PREPARING BILE ACIDS | MEDYTOX INC (KR) | 2023-11-29 | — | — | EP | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023179521-A1 | POLYMER-DRUG CONJUGATES | PRIMELINK BIOTHERAPEUTICS (SHENZHEN) CO., LTD (CN) | 2023-09-28 | — | — | WO | disclosed |
| US-20230279476-A1 | NOVEL ACRYLATE DERIVATIVES AND USES THEREOF | EXPANSION TECHNOLOGIES (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230270871-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | AGENSYS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3969459-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF ELDECALCITOL | FAES FARMA SA (ES) | 2023-08-23 | — | — | EP | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-20230210856-A1 | METHODS OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | MADRIGAL PHARMACEUTICALS, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023118045-A1 | PROCESS FOR THE CONTROLLED SYNTHESIS OF VOCLOSPORIN | CURIA SPAIN, S.A.U. (ES) | 2023-06-29 | — | — | WO | disclosed |
| EP-4201952-A1 | PROCESS FOR THE CONTROLLED SYNTHESIS OF VOCLOSPORIN | CURIA SPAIN, S.A.U. (ES) | 2023-06-28 | — | — | EP | disclosed |
| EP-4200309-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | ATEA Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20230192597-A1 | Amorphous Solid Succinylated 3-(Fatty Acid Amido)-2-Hydroxy-1-(Protected Hydroxy)-Propane Salts and Methods of Making the Same | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2023-06-22 | — | — | US | disclosed |
| CN-116209464-A | Markers for use in methods of treating cancer with Antibody Drug Conjugates (ADCs) | 艾更斯司股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-4168039-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | Agensys, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11634503-B2 | Antibody drug conjugates (ADC) that bind to 158P1D7 proteins | AGENSYS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11633500-B2 | Antibody drug conjugates (ADC) that bind to CD37 proteins | AGENSYS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2023056089-A1 | IMMUNOLOGICAL ADJUVANT FORMULATIONS COMPRISING TLR4 AGONIST E6020 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-04-06 | — | — | WO | disclosed |
| CN-115884977-A | Stereoselective preparation of selected purine phosphoramidates | 阿堤亚制药公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11607460-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-11591280-B2 | Process and intermediates for the preparation of eldecalcitol | FAES FARMA, S.A. | 2023-02-28 | — | — | US | disclosed |
| US-20230055040-A1 | Synthesis Of Benzodiazepine Derivatives | TRIO MEDICINES LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| CN-115707698-A | 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-formamide compound, and preparation method and application thereof | 辽宁何氏医学院 | 2023-02-21 | — | — | CN | disclosed |
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230033859-A1 | CD19 BINDING AGENTS AND USES THEREOF | SEAGEN INC (US) | 2023-02-02 | — | — | US | disclosed |
| US-11564926-B2 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | MADRIGAL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20230025600-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11559582-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-111328332-B | Process for the preparation of bile acids | 玫帝托克斯股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20230001005-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ANGION BIOMEDICA CORP. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220401563-A1 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | CITY OF HOPE | 2022-12-22 | — | — | US | disclosed |
| US-11530179-B2 | Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1 -(protected hydroxy)-propane salts and methods of making the same | GERON CORPORATION (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3271468-B1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION SL (ES) | 2022-12-14 | — | — | EP | disclosed |
| CN-115397473-A | Treatment of cancer with Antibody Drug Conjugates (ADC) capable of binding 191P4D12 protein | 艾更斯司股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-11504359-B2 | Antifibrotic compounds and uses thereof | ANGION BIOMEDICA CORP. (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3813832-B1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | FUNDACIO HOSPITAL UNIV VALL DHEBRON INSTITUT DE RECERCA (ES) | 2022-11-09 | — | — | EP | disclosed |
| US-20220347200-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2022-11-03 | — | — | US | disclosed |
| US-20220347199-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2022-11-03 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11464865-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | CITY OF HOPE (US) | 2022-10-11 | — | — | US | disclosed |
| EP-4065173-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-11459319-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11447454-B2 | Synthesis of benzodiazepine derivatives | TRIO MEDICINES LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2022-09-08 | — | — | US | disclosed |
| EP-4051252-A1 | CRYSTALLINE SOLIDS OF 3-PALMITOYL-AMIDO-1,2-PROPANEDIOL AND 3-PALMITOYL-AMIDO-2-HYDROXY-1-DIMETHOXYTRIPHENYLMETHYLETHER-PROPANE AND METHODS OF MAKING AND USING THE SAME | GERON CORPORATION (US) | 2022-09-07 | — | — | EP | disclosed |
| EP-4051242-A1 | AMORPHOUS SOLID SUCCINYLATED 3-(FATTY ACID AMIDO)-2-HYDROXY-1-(PROTECTED HYDROXY)-PROPANE SALTS AND METHODS OF MAKING THE SAME | GERON CORPORATION (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-115010915-A | Nitrogen branched nine-arm polyethylene glycol derivative, preparation method and biological related substance modified by nitrogen branched nine-arm polyethylene glycol derivative | 厦门赛诺邦格生物科技股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-11434234-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2022-09-06 | — | — | US | disclosed |
| EP-3520816-B1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | TAKEDA PHARMACEUTICALS CO (JP) | 2022-08-31 | — | — | EP | disclosed |
| CN-114901690-A | Treatment of cancer with Antibody Drug Conjugates (ADCs) that bind 191P4D12 protein | 艾更斯司股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114901269-A | Crystalline solids of 3-palmitoyl-amido-1, 2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same | 美国杰龙生物医药公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114845992-A | Amorphous solid succinylated 3- (fatty acid amido) -2-hydroxy-1- (protected hydroxy) -propane salts and process for their preparation | 美国杰龙生物医药公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-110591079-B | Preparation method of monofunctional nonlinear polyethylene glycol | 厦门赛诺邦格生物科技股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-4023641-A2 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | Madrigal Pharmaceuticals, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220204433-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF ELDECALCITOL | FAES FARMA, S.A. (ES) | 2022-06-30 | — | — | US | disclosed |
| EP-4013795-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220175950-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| EP-4003340-A2 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | Angion Biomedica Corp. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11331394-B2 | CD19 binding agents and uses thereof | SEAGEN INC. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-114502163-A | Ethynylheterocycles as RHO-related coiled coil kinase (ROCK) inhibitors | 安吉昂生物医药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022099284-A1 | NOVEL CAPSAICIN ANALOGS AND USES THEREOF | YOUNG BIOPHARMA, LLC (US) | 2022-05-12 | — | — | WO | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| CN-110204558-B | Synthesis of cephalosporin compounds | 默沙东公司 | 2022-05-06 | — | — | CN | disclosed |
| US-11312708-B2 | Process and intermediates for the preparation of benzo[b]thiophene compounds | CRYSTAL PHARMA, S.A.U. (ES) | 2022-04-26 | — | — | US | disclosed |
| CN-114224907-A | Compounds and compositions comprising phosphorothioated oligodeoxynucleotides and methods of use thereof | 希望之城 | 2022-03-25 | — | — | CN | disclosed |
| US-20220071917-A9 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-03-10 | — | — | US | disclosed |
| US-20220073493-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VOXELOTOR | CURIA SPAIN, S.A.U. (ES) | 2022-03-10 | — | — | US | disclosed |
| WO-2022040473-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220056008-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR | CRYSTAL PHARMA, S.A.U. (ES) | 2022-02-24 | — | — | US | disclosed |
| CN-109963833-B | Process for the preparation of mono-protected alpha, omega-diaminoalkanes | 拜奥迪斯私人有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-110643032-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-107849594-B | Deamination of organophosphorus nucleosides | 科技学专业学院有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20220009957-A1 | Methods for Preparing Bile Acids | MEDYTOX INC. (KR) | 2022-01-13 | — | — | US | disclosed |
| CN-113853378-A | Process and intermediates for preparing eldecalcitol | 费斯制药股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| WO-2021257938-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | AGENSYS, INC, (US) | 2021-12-23 | — | — | WO | disclosed |
| CN-107980001-B | Compounds and compositions comprising phosphorothioated oligodeoxynucleotides and methods of use thereof | 希望之城 | 2021-12-17 | — | — | CN | disclosed |
| EP-3114112-B1 | CRYSTALLINE DERIVATIVES OF (S)-1-((2R,3R,4S,5S)-5-ALLYL-3-METHOXY-4-(TOSYLMETHYL)TETRAHYDROFURAN-2-YL)-3-AMINOPROPAN-2-OL | ALPHORA RES INC (CA) | 2021-12-15 | — | — | EP | disclosed |
| CN-113784721-A | High activity compound for resisting COVID-19 | 阿堤亚制药公司 | 2021-12-10 | — | — | CN | disclosed |
| EP-3689853-B1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | MADRIGAL PHARMACEUTICALS INC (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-113677364-A | Pharmaceutical compositions comprising anti-191P 4D12 antibody drug conjugates and methods of use thereof | 艾更斯司股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3903812-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| US-11161872-B2 | Methods for preparing bile acids | MEDYTOX INC. (KR) | 2021-11-02 | — | — | US | disclosed |
| WO-2021216722-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3898608-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR | Crystal Pharma, S.A.U. (ES) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898618-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VOXELOTOR | Crystal Pharma, S.A.U. (ES) | 2021-10-27 | — | — | EP | disclosed |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. | 2021-10-21 | — | — | US | disclosed |
| EP-3890778-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | Agensys, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| CN-113429559-A | Six-arm polyethylene glycol derivative with end hetero-functionalized and preparation method thereof | 厦门赛诺邦格生物科技股份有限公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-109705124-B | Radioactive fluorine labeled Larotrectinib compound and preparation method thereof | 上海健康医学院 | 2021-09-24 | — | — | CN | disclosed |
| US-20210283268-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| CN-113365664-A | Cysteine engineered antibody-drug conjugates with peptide-containing linkers | 梅尔莎纳医疗公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-113365992-A | Processes and intermediates for the preparation of vortiotropium | 晶体制药独资有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-107531631-B | Methods and agents for treating diseases | 安吉昂生物医药公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20210253566-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-08-19 | — | — | US | disclosed |
| CN-113272290-A | Process and intermediates for synthesis of vortiotropium | 晶体制药独资有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20210228494-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2021-07-29 | — | — | US | disclosed |
| US-20210230150-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | AMIRA THERAPEUTICS, S.L. (ES) | 2021-07-29 | — | — | US | disclosed |
| EP-3305900-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| EP-3409287-B9 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-11059835-B2 | Synthesis of cephalosporin compounds | MERCK SHARP & DOHME CORP. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-06-10 | — | — | US | disclosed |
| WO-2021108353-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210161904-A1 | METHODS OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2021-06-03 | — | — | US | disclosed |
| CN-108530636-B | Single functionalized branched polyethylene glycol | 厦门赛诺邦格生物科技股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20210147344-A1 | AMORPHOUS SOLID SUCCINYLATED 3-(FATTY ACID AMIDO)-2-HYDROXY-1-(PROTECTED HYDROXY)-PROPANE SALTS AND METHODS OF MAKING THE SAME | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2021-05-20 | — | — | US | disclosed |
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210145979-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS | AGENSYS, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147342-A1 | CRYSTALLINE SOLIDS OF 3-PALMITOYL-AMIDO-1,2-PROPANEDIOL AND 3-PALMITOYL-AMIDO-2-HYDROXY-1-DIMETHOXYTRIPHENYLMETHYLETHER-PROPANE AND METHODS OF MAKING AND USING THE SAME | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2021-05-20 | — | — | US | disclosed |
| EP-3331865-B1 | SYNTHESIS OF BENZODIAZEPINE DERIVATIVES | TRIO MEDICINES LTD (GB) | 2021-05-12 | — | — | EP | disclosed |
| EP-3180335-B1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112694608-A | Six-arm polyethylene glycol derivative, preparation method and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2021-04-23 | — | — | CN | disclosed |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10973936-B2 | 18F-saccharide-folates | Merck & Cie (CH) | 2021-04-13 | — | — | US | disclosed |
| EP-3409287-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20210095043-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| CN-108530637-B | Preparation method of single-functionalized branched polyethylene glycol | 厦门赛诺邦格生物科技股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10941211-B2 | Anti-GCC antibody molecules and related compositions and methods | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| WO-2021030240-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210038733-A1 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | CITY OF HOPE | 2021-02-11 | — | — | US | disclosed |
| US-10906884-B2 | Benzodiazepine derivatives as CCK2/gastrin receptor antagonists | TRIO MEDICINES LTD (GB) | 2021-02-02 | — | — | US | disclosed |
| WO-2021016256-A2 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. (US) | 2021-01-28 | — | — | WO | disclosed |
| US-10899750-B2 | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity | ANGION BIOMEDICA CORP. (US) | 2021-01-26 | — | — | US | disclosed |
| US-10894090-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894050-B2 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | MADRIGAL PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| CN-106458947-B | Crystalline derivatives of (S) -1- ((2R,3R,4S,5S) -5-allyl-3-methoxy-4- (tosylmethyl) tetrahydrofuran-2-yl) -3-aminopropan-2-ol | 阿方拉研究股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-RE48389-E1 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3538510-B1 | PROCESS FOR THE PREPARATION OF MONO-PROTECTED ALPHA,OMEGA-DIAMINO ALKANES | BYONDIS BV (NL) | 2021-01-06 | — | — | EP | disclosed |
| US-20200385404-A1 | SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | US | disclosed |
| US-10851095-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2020-12-01 | — | — | US | disclosed |
| CN-108530617-B | Branched polyethylene glycol heterobifunctional derivative, preparation method thereof and two-component bio-related substance conjugate thereof | 厦门赛诺邦格生物科技股份有限公司 | 2020-11-27 | — | — | CN | disclosed |
| US-20200369712-A1 | METHODS FOR PREPARING BILE ACIDS | WUXI APPTEC (SHANGHAI) CO., LTD. (CN) | 2020-11-26 | — | — | US | disclosed |
| US-10815194-B2 | Process for the preparation of mono-protected α,ω-diamino alkanes | BYONDIS B.V. (NL) | 2020-10-27 | — | — | US | disclosed |
| EP-3180347-B1 | SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3703666-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | Universidade de Santiago de Compostela (ES) | 2020-09-09 | — | — | EP | disclosed |
| EP-3268353-B1 | PYRAZOLYL DERIVATIVES AS PEST CONTROL AGENTS | BAYER ANIMAL HEALTH GMBH (DE) | 2020-09-09 | — | — | EP | disclosed |
| US-10758624-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | CITY OF HOPE (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3689853-A1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | Madrigal Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200231576-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2020-07-23 | — | — | US | disclosed |
| US-20200223807-A1 | Synthesis Of Benzodiazepine Derivatives | TRIO MEDICINES LIMITED (GB) | 2020-07-16 | — | — | US | disclosed |
| CN-111406051-A | Vinylheterocycles as RHO-associated coiled coil kinase (ROCK) inhibitors | 安吉昂生物医药公司 | 2020-07-10 | — | — | CN | disclosed |
| US-20200216836-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2020-07-09 | — | — | US | disclosed |
| EP-3676262-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | Angion Biomedica Corp. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-RE48077-E1 | Methods of treating ototoxicity | ANIDA PHARMA INC. (US) | 2020-07-07 | — | — | US | disclosed |
| CN-111330017-A | Antibody Drug Conjugates (ADC) that bind to 158P1D7 protein | 艾更斯司股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-111330016-A | Antibody Drug Conjugates (ADC) that bind to 158P1D7 protein | 艾更斯司股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| WO-2020127924-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VOXELOTOR | BIONICE, S.L.U. (ES) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127945-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR | BIONICE, S.L.U. (ES) | 2020-06-25 | — | — | WO | disclosed |
| CN-111328332-A | Process for the preparation of bile acids | 玫帝托克斯股份有限公司 | 2020-06-23 | — | — | CN | disclosed |
| WO-2020117373-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20200172523-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CURIA SPAIN, S.A.U. (ES) | 2020-06-04 | — | — | US | disclosed |
| US-10669348-B2 | Antibody drug conjugates (ADC) that bind to 158P1D7 proteins | AGENSYS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10662202-B2 | Synthesis of cephalosporin compounds | MERCK SHARP & DOHM CORP. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| CN-106563128-B | Use of auristatin-based antibody drug conjugates and mTOR-binding inhibitors in the manufacture of a medicament for the treatment of cancer | 西雅图遗传学公司 | 2020-05-22 | — | — | CN | disclosed |
| US-10646583-B2 | Antibody drug conjugates (ADC) that bind to CD37 proteins | AGENSYS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10632099-B2 | Non-aromatic difluoro analogues of resorcylic acid lactones | UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3640236-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2020-04-22 | — | — | EP | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-2895466-B1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | MADRIGAL PHARMACEUTICALS INC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10597386-B2 | Process and intermediates for the preparation of benzo[b]thiophene compounds | CRYSTAL PHARMA, S.A.U. (ES) | 2020-03-24 | — | — | US | disclosed |
| US-20200071321-A1 | METHODS AND USES OF COMPOUNDS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200069662-A1 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10570102-B2 | Synthesis of benzodiazepine derivatives | TRIO MEDICINES LIMITED (GB) | 2020-02-25 | — | — | US | disclosed |
| EP-2490720-B1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | MILLENNIUM PHARM INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10556893-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2020-02-11 | — | — | US | disclosed |
| EP-3604307-A1 | ANTI-FIBROTIC COMPOUNDS AND USES THEREOF | Angion Biomedica Corp. (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-105073132-B | Antibody Drug Conjugates (ADC) that bind to 158P1D7 protein | 艾更斯司股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-110643032-A | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2020-01-03 | — | — | CN | disclosed |
| CN-110591079-A | Preparation method of monofunctional nonlinear polyethylene glycol | 厦门赛诺邦格生物科技股份有限公司 | 2019-12-20 | — | — | CN | disclosed |
| EP-2961401-B1 | METHODS OF TREATING OTOTOXICITY | ANIDA PHARMA INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10471020-B2 | Nanoparticles with protected interiors, and methods of use thereof | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2019-11-12 | — | — | US | disclosed |
| US-20190330618-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2019-10-31 | — | — | US | disclosed |
| US-20190328898-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS INC (US) | 2019-10-31 | — | — | US | disclosed |
| EP-3180326-B1 | BENZODIAZEPINE DERIVATIVES AS CCK2/GASTRIN RECEPTOR ANTAGONISTS | TRIO MEDICINES LTD (GB) | 2019-10-23 | — | — | EP | disclosed |
| US-10434085-B2 | Non-aromatic difluoro analogues of resorcylic acid lactones | UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2019-10-08 | — | — | US | disclosed |
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2019-10-08 | — | — | US | disclosed |
| EP-2664324-B1 | NANOCAPSULES WITH A POLYMER SHELL | UNIV SANTIAGO COMPOSTELA (ES) | 2019-09-25 | — | — | EP | disclosed |
| EP-3538510-A1 | PROCESS FOR THE PREPARATION OF MONO-PROTECTED alpha,omega-DIAMINO ALKANES | Synthon Biopharmaceuticals B.V. (NL) | 2019-09-18 | — | — | EP | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-10414760-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414745-B2 | Phenol derivatives to treat cancer | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2019-09-17 | — | — | US | disclosed |
| EP-2595948-B1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LTD (IE) | 2019-09-04 | — | — | EP | disclosed |
| EP-2814479-B1 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | ANIDA PHARMA INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20190263831-A1 | SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190255200-A1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2019-08-22 | — | — | US | disclosed |
| US-10376517-B2 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | MADRIGAL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| EP-3520816-A2 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | Millennium Pharmaceuticals, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190233391-A1 | Benzodiazepine Derivatives As CCK2/Gastrin Receptor Antagonists | TRIO MEDICINES LTD (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20190184029-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEAGEN INC. | 2019-06-20 | — | — | US | disclosed |
| US-10322195-B2 | 18F-saccharide-folates | Merck & Cie (CH) | 2019-06-18 | — | — | US | disclosed |
| EP-3494996-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | Agensys, Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10308627-B2 | Benzodiazepine derivatives as CCK2/gastrin receptor antagonists | TRIO MEDICINES LTD (GB) | 2019-06-04 | — | — | US | disclosed |
| US-10301274-B2 | Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-YL)-3-aminopropan-2-ol | SANDOZ AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-10299478-B2 | Pyrazolyltriazolylpyridines as pesticides | BAYER ANIMAL HEALTH GMBH (DE) | 2019-05-28 | — | — | US | disclosed |
| EP-2629801-B1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEATTLE GENETICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10287576-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2019-05-14 | — | — | US | disclosed |
| US-10287282-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190134022-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190125731-A1 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| US-10273226-B2 | Pyrazolyl-heteroarylamides as pesticides | BAYER ANIMAL HEALTH GMBH (DE) | 2019-04-30 | — | — | US | disclosed |
| EP-3157913-B1 | PYRAZOLYL TRIAZOLYL PYRIDINES AS PESTICIDE | BAYER ANIMAL HEALTH GMBH (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-10226535-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2019046795-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-2928503-B1 | CONJUGATES OF AURISTATIN COMPOUNDS | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2928504-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2931316-B1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10202351-B2 | Pyrazolyl derivatives as pest control agents | BAYER ANIMAL HEALTH GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| US-10201615-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEATTLE GENETICS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190040048-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CURIA SPAIN, S.A.U. (ES) | 2019-02-07 | — | — | US | disclosed |
| US-10195184-B2 | Antifibrotic compounds and uses thereof | ANGION BIOMEDICA CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| CN-105008335-B | Method for synthesizing thyroid hormone analogue and its polymorph | 马德里加尔制药公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-2887959-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180355062-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-12-13 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-3409287-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180334455-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2018-11-22 | — | — | US | disclosed |
| US-20180326087-A1 | CD19 BINDING AGENTS AND USES THEREOF | SEAGEN INC. | 2018-11-15 | — | — | US | disclosed |
| US-10125149-B2 | Synthesis of cephalosporin compounds | MERCK SHARP & DOHME CORP. (US) | 2018-11-13 | — | — | US | disclosed |
| US-10124000-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2018-11-13 | — | — | US | disclosed |
| EP-3395361-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | Agensys, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| US-RE47103-E1 | Antibody drug conjugates (ADC) that bind to 158P1D7 proteins | AGENSYS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180296693-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | SEAGEN INC. | 2018-10-18 | — | — | US | disclosed |
| US-20180273571-A1 | CONCISE SYNTHESIS OF UREA DERIVATIVES OF AMPHOTERICIN B | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2018-09-27 | — | — | US | disclosed |
| EP-2776382-B1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2018-09-19 | — | — | EP | disclosed |
| US-20180251566-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | SEAGEN INC. | 2018-09-06 | — | — | US | disclosed |
| US-20180243428-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20180243427-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2018-08-30 | — | — | US | disclosed |
| US-10059680-B2 | Thiadiazolyl-oximinoacetic acid derivative compounds | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180236096-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS | AGENSYS, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180237400-A1 | Synthesis Of Benzodiazepine Derivatives | TRIO MEDICINES LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| EP-3356342-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | Crystal Pharma, S.A.U. (ES) | 2018-08-08 | — | — | EP | disclosed |
| US-20180215728-A1 | Benzodiazepine Derivatives As CCK2/Gastrin Receptor Antagonists | TRIO MEDICINES LTD (GB) | 2018-08-02 | — | — | US | disclosed |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| US-10035774-B2 | Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds | MERCK SHARP & DOHME CORP. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180185497-A1 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | CITY OF HOPE (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180170949-A1 | SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-06-21 | — | — | US | disclosed |
| EP-3331865-A1 | SYNTHESIS OF BENZODIAZEPINE DERIVATIVES | Trio Medicines Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| US-20180153854-A1 | NON-AROMATIC DIFLUORO ANALOGUES OF RESORCYLIC ACID LACTONES | NORTH CAROLINA AT GREENSBORO, UNIVERSITY OF | 2018-06-07 | — | — | US | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| EP-2621526-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS INC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9987244-B2 | Methods of treating ototoxicity | ANIDA PHARMA, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988374-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988417-B2 | Process for the preparation of estetrol | CRYSTAL PHARMA, S.A.U. (ES) | 2018-06-05 | — | — | US | disclosed |
| US-20180148427-A1 | PHENOL DERIVATIVES TO TREAT CANCER | FUNDACION MEDINA CENTRO DE EXCELENCIA DE MEDICAMENTOS INNOVA (ES) | 2018-05-31 | — | — | US | disclosed |
| US-20180148438-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2018-05-31 | — | — | US | disclosed |
| WO-2018086993-A1 | PROCESS FOR THE PREPARATION OF MONO-PROTECTED alpha,omega-DIAMINO ALKANES | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-05-17 | — | — | WO | disclosed |
| EP-3089972-B1 | NOVEL PYRAZOLE HETEROARYLAMIDES AS PESTICIDES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-05-16 | — | — | EP | disclosed |
| US-9968612-B2 | Method of synthesizing thyroid hormone analogs and polymorphs thereof | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| EP-3316894-A1 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | City of Hope (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9962454-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| EP-3138844-B1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | EISAI R&D MAN CO LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-3315531-A1 | 8-ARM POLYETHYLENE GLYCOL DERIVATIVE, MANUFACTURING METHOD AND MODIFIED BIO-RELATED SUBSTANCE THEREBY | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2018-05-02 | — | — | EP | disclosed |
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| EP-3305900-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | Nuevolution A/S (DK) | 2018-04-11 | — | — | EP | disclosed |
| EP-2533804-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20180093982-A1 | METHODS AND USES OF COMPOUNDS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2018-04-05 | — | — | US | disclosed |
| US-9926376-B2 | Antibody drug conjugates (ADC) that bind to 158P1D7 proteins | AGENSYS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925273-B2 | Antibody drug conjugates (ADC) that bind to CD37 proteins | AGENSYS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180078510-A1 | NANOPARTICLES WITH PROTECTED INTERIORS, AND METHODS OF USE THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2018-03-22 | — | — | US | disclosed |
| EP-2855421-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES | CRYSTAL PHARMA SAU (ES) | 2018-03-21 | — | — | EP | disclosed |
| US-9919061-B2 | CD19 binding agents and uses thereof | SEATTLE GENETICS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20180066295-A1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION, S.L.U. (ES) | 2018-03-08 | — | — | US | disclosed |
| EP-3288929-A1 | PHENOL DERIVATIVES TO TREAT CANCER | FUNDACIÓN MEDINA. Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía (ES) | 2018-03-07 | — | — | EP | disclosed |
| US-20180044298-A1 | NOVEL PYRAZOLYL DERIVATIVES AS PEST CONTROL AGENTS | BAYER ANIMAL HEALTH GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| EP-3271468-A1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2018-01-24 | — | — | EP | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3268353-A1 | PYRAZOLYL-DERIVATIVES AS PEST CONTROL AGENTS | Bayer Animal Health GmbH (DE) | 2018-01-17 | — | — | EP | disclosed |
| US-20180008581-A1 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2018-01-11 | — | — | US | disclosed |
| US-20180009793-A1 | METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | ANGION BIOMEDICA CORP (US) | 2018-01-11 | — | — | US | disclosed |
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180000961-A9 | CD19 BINDING AGENTS AND USES THEREOF | SEAGEN INC. | 2018-01-04 | — | — | US | disclosed |
| US-20170369459-A1 | THIADIAZOLYL - OXIMINOACETIC ACID DERIVATIVE COMPOUNDS | Merck Sharp & Dohme Corpl (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170362183-A1 | PYRAZOLYL CARBOXYLIC ACID AND PYRAZOLYL UREA DERIVATIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2017207648-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OBETICHOLIC ACID AND DERIVATIVES THEREOF | BIONICE, S.L.U (ES) | 2017-12-07 | — | — | WO | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| EP-3004036-B1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LTD (IE) | 2017-11-22 | — | — | EP | disclosed |
| EP-3242554-A1 | CONCISE SYNTHESIS OF UREA DERIVATIVES OF AMPHOTERICIN B | The Board of Trustees of the University of Illionis (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-3240778-A1 | METHODS AND AGENTS FOR TREATING DISEASE | Angion Biomedica Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-2953942-B1 | HALOGEN-SUBSTITUTED PYRAZOLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2017-10-25 | — | — | EP | disclosed |
| EP-3228325-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | Mersana Therapeutics, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170275300-A1 | SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170247363-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247688-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2017-08-31 | — | — | US | disclosed |
| EP-2794573-B1 | NOVEL INSECTICIDAL AROMATIC AMIDES | BAYER IP GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2964631-B1 | HALOGEN-SUBSTITUTED N-[3-(1H-PYRAZOL-4-YL)PHENYLMETHYL]-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PESTICIDES FOR USE IN CROP PROTECTION IN VETERINARY MEDICINE AND IN MATERIAL PROTECTION | BAYER ANIMAL HEALTH GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2341140-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | disclosed |
| EP-2336315-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | disclosed |
| US-9706775-B2 | Halogen-substituted compounds | BAYER ANIMAL HEALTH GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| EP-3180335-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | Angion Biomedica Corporation (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3180347-A1 | SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9676698-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2017-06-13 | — | — | US | disclosed |
| US-9675070-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9663471-B2 | Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity | ANGION BIOMEDICA CORPORATION (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170137413-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-05-18 | — | — | US | disclosed |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| WO-2017070536-A1 | METHODS AND AGENTS FOR TREATING DISEASES | ANGION BIOMEDICA CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170112129-A1 | NOVEL PYRAZOLYLTRIAZOLYLPYRIDINES AS PESTICIDES | ELANCO ANIMAL HEALTH GMBH (DE) | 2017-04-27 | — | — | US | disclosed |
| EP-3157913-A1 | PYRAZOLYL-TRIAZOLYL-PYRIDINES AS PEST-CONTROL AGENTS | Bayer Animal Health GmbH (DE) | 2017-04-26 | — | — | EP | disclosed |
| US-20170105957-A1 | Methods of Treating Ototoxicity | ANIDA PHARMA INC (US) | 2017-04-20 | — | — | US | disclosed |
| EP-3150591-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | Crystal Pharma S.A.U (ES) | 2017-04-05 | — | — | EP | disclosed |
| US-9597321-B2 | Antifibrotic compounds and uses thereof | ANGION BIOMEDICA CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170066735-A1 | Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-YL)-3-aminopropan-2-ol | ALPHORA RESEARCH INC. (CA) | 2017-03-09 | — | — | US | disclosed |
| EP-2717916-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138844-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | Eisai R&D Management Co., Ltd. (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2308861-B1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI R&D MAN CO LTD (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9574189-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2017-02-21 | — | — | US | disclosed |
| WO-2017025727-A1 | SYNTHESIS OF BENZODIAZEPINE DERIVATIVES | TRIO MEDICINES LIMITED (GB) | 2017-02-16 | — | — | WO | disclosed |
| EP-3046928-B1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA SAU (ES) | 2017-02-08 | — | — | EP | disclosed |
| EP-3126353-A1 | NOVEL 3-[(PYRAZOL-5-YL)-HETEROARYL]-BENZAMIDE DERIVATIVES AND USE THEREOF AS PEST CONTROL AGENTS | Bayer CropScience Aktiengesellschaft (DE) | 2017-02-08 | — | — | EP | disclosed |
| EP-3114112-A1 | CRYSTALLINE DERIVATIVES OF (S)-1-((2R,3R,4S,5S)-5-ALLYL-3-METHOXY-4-(TOSYLMETHYL)TETRAHYDROFURAN-2-YL)-3-AMINOPROPAN-2-OL | Alphora Research Inc. (CA) | 2017-01-11 | — | — | EP | disclosed |
| WO-2017004357-A1 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | CITY OF HOPE (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20160369003-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| EP-2964632-B1 | HALOGEN SUBSTITUTED 1H-PYRAZOLE DERIVATIVES AS INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2016-12-14 | — | — | EP | disclosed |
| WO-2016196256-A2 | NON-AROMATIC DIFLUORO ANALOGUES OF RESORCYLIC ACID LACTONES | UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160357901-A1 | PEPTIDOMIMETIC COMPOUNDS AND RELATED METHODS | BURGESS KEVIN (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160340298-A1 | NOVEL COMPOUNDS | AVANTI POLAR LIPIDS, INC. | 2016-11-24 | — | — | US | disclosed |
| EP-2352723-B1 | PESTICIDAL N-ARYL- OR N-HETEROARYL PYRAZOLE CARBOXAMIDE COMPOUNDS | BAYER IP GMBH (DE) | 2016-11-23 | — | — | EP | disclosed |
| EP-2019674-B1 | HISTONE DEACETYLASE AND TUBULIN DEACETYLASE INHIBITORS | HARVARD COLLEGE (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-1910387-B1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | EISAI R&D MAN CO LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326140-A1 | NOVEL PYRAZOLYL-HETEROARYLAMIDES AS PESTICIDES | BAYER ANIMAL HEALTH GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| EP-3089972-A1 | NOVEL PYRAZOLYL-HETEROARYLAMIDES AS PESTICIDES | Bayer Animal Health GmbH (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-9487489-B2 | Halogen-substituted pyrazole derivatives as pest-control agents | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-11-08 | — | — | US | disclosed |
| WO-2016174226-A1 | PHENOL DERIVATIVES TO TREAT CANCER | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2016-11-03 | — | — | WO | disclosed |
| EP-3088396-A1 | PHENOL DERIVATIVES TO TREAT CANCER | FUNDACIÓN MEDINA. Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía (ES) | 2016-11-02 | — | — | EP | disclosed |
| US-9468620-B2 | Methods of treating ototoxicity | Andida Pharma, Inc. (US) | 2016-10-18 | — | — | US | disclosed |
| CN-103561759-B | Synergistic effect between AURISTATIN (AURISTATIN) -based antibody drug conjugates and PI3K-AKT mTOR pathway inhibitors | 西雅图遗传学公司 | 2016-10-12 | — | — | CN | disclosed |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2016-09-29 | — | — | US | disclosed |
| WO-2016146808-A1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | INSTITUT UNIV. DE CIÈNCIA I TECNOLOGIA, S. A. (ES) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016142394-A1 | PYRAZOLYL-DERIVATIVES AS PEST CONTROL AGENTS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-09-15 | — | — | WO | disclosed |
| US-20160263243-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | SEAGEN INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160256563-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9434686-B2 | Deacetylase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160243126-A1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2016-08-25 | — | — | US | disclosed |
| EP-2292227-B1 | Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity | ANGION BIOMEDICA CORP (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9422228-B2 | Process for the preparation of optically pure fesoterodine derivatives | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-23 | — | — | US | disclosed |
| EP-2211904-B1 | CD19 BINDING AGENTS AND USES THEREOF | SEATTLE GENETICS INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9416084-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2016-08-16 | — | — | US | disclosed |
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-11 | — | — | US | disclosed |
| US-20160220693-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEAGEN INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160220696-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-9403760-B2 | Compounds | AVANTI POLAR LIPIDS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| WO-2016112260-A1 | CONCISE SYNTHESIS OF UREA DERIVATIVES OF AMPHOTERICIN B | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016109492-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109259-A2 | SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185717-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2016-06-30 | — | — | US | disclosed |
| WO-2016095860-A1 | PYRAZOLYL CARBOXYLIC ACID AND PYRAZOLYL UREA DERIVATIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100897-A1 | THIADIAZOLYL-OXIMINOACETIC ACID DERIVATIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-9340483-B2 | Methods of treating amyotrophic lateral sclerosis | ANIDA PHARMA INC. (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2374454-B1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI R&D MAN CO LTD (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2321264-B1 | DEACETYLASE INHIBITORS AND USES THEREOF | HARVARD COLLEGE (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20160107977-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LIMITED (IE) | 2016-04-21 | — | — | US | disclosed |
| US-9314538-B2 | Nucleic acid molecules encoding antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9308278-B2 | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins | AGENSYS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| CN-103502221-B | N- (3-carbamoylphenyl) -1H-pyrazole-5-carboxamide derivatives and their use for controlling animal pests | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-30 | — | — | CN | disclosed |
| US-9295739-B2 | Folate conjugates of albumin-binding entities | Merck & Cie (CH) | 2016-03-29 | — | — | US | disclosed |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-9272052-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEATTLE GENETICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160051694-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS | AGENSYS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-9266861-B2 | Method of synthesizing thyroid hormone analogs and polymorphs thereof | MADRIGAL PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| WO-2016025839-A1 | SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025424-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORPORATION (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160038490-A1 | COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | ANGION BIOMEDICA CORP. (US) | 2016-02-11 | — | — | US | disclosed |
| US-9254339-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9248126-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20160022829-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024001-A1 | NOVEL COMPOUNDS | AVANTI POLAR LIPIDS INC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2686303-B1 | N-(3-CARBAMOYLPHENYL)-1H-PYRAZOLE-5-CARBOXAMIDE DERIVATIVES AND THEIR USE FOR COMBATING ANIMAL PESTS | BAYER IP GMBH (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-20160007604-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-01-14 | — | — | US | disclosed |
| US-20160009727-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| EP-2964632-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | Bayer CropScience Aktiengesellschaft (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2964631-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | Bayer Animal Health GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002208-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-20160000742-A1 | METHODS OF TREATING OTOTOXICITY | ANIDA PHARMA INC. | 2016-01-07 | — | — | US | disclosed |
| EP-2961401-A1 | METHODS OF TREATING OTOTOXICITY | Anida Pharma Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2959898-A1 | 4,5-DIOXO-NAPHTHO[1,2-b]FURANS AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2015193216-A1 | PYRAZOLYL-TRIAZOLYL-PYRIDINES AS PEST-CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | disclosed |
| US-9216174-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2953942-A1 | HALOGEN-SUBSTITUTED PYRAZOL DERIVATIVES AS PEST-CONTROL AGENTS | Bayer CropScience Aktiengesellschaft (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-20150353500-A1 | HALOGEN-SUBSTITUTED PYRAZOL DERIVATIVES AS PEST-CONTROL AGENTS | VETOQUINOL SA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-9204645-B2 | Insecticidal aromatic amides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| WO-2015181116-A1 | PROCESS AND INTERMEDIADES FOR THE PREPARATION OF 7-ALKYLATED STEROIDS | CRYSTAL PHARMA, S.A.U. (ES) | 2015-12-03 | — | — | WO | disclosed |
| US-9201067-B2 | Size-controlled macromolecule | POSCO (KR) | 2015-12-01 | — | — | US | disclosed |
| CN-1882701-B | Size-controlled macromole | POSCO (KR) | 2015-11-25 | — | — | CN | disclosed |
| US-20150315118-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2015-11-05 | — | — | US | disclosed |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150306240-A1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20150306245-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150306078-A1 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2015-10-29 | — | — | US | disclosed |
| CN-105008335-A | Method for synthesizing thyroid hormone analogue and its polymorph | MADRIGAL PHARMACEUTICALS INC | 2015-10-28 | — | — | CN | disclosed |
| US-9168237-B2 | Adamantyl derivatives as therapeutic agents | WOMEN & INFANTS' HOSPITAL OF RHODE ISLAND (US) | 2015-10-27 | — | — | US | disclosed |
| EP-1991247-B1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HARVARD COLLEGE (US) | 2015-10-14 | — | — | EP | disclosed |
| WO-2015150442-A1 | NOVEL 3-[(PYRAZOL-5-YL)-HETEROARYL]-BENZAMIDE DERIVATIVES AND USE THEREOF AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AG (DE) | 2015-10-08 | — | — | WO | disclosed |
| US-20150283255-A1 | CD19 BINDING AGENTS AND USES THEREOF | SEATTLE GENETICS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-9144615-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2010556-B1 | HOMOGENEOUS ERYTHROPOIETIN AND METHOD FOR THEIR PREPARATION | SLOAN KETTERING INST CANCER (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2015131286-A1 | CRYSTALLINE DERIVATIVES OF (S)-1-((2R,3R,4S,5S)-5-ALLYL-3-METHOXY-4-(TOSYLMETHYL)TETRAHYDROFURAN-2-YL)-3-AMINOPROPAN-2-OL | ALPHORA RESEARCH INC. (CA) | 2015-09-11 | — | — | WO | disclosed |
| US-9126945-B2 | N-(3-carbamoylphenly)-1H-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| CN-104877127-A | Eight-armed polyethylene glycol derivative, preparation method and related biological substance modified by derivative | XIAMEN SINOPEG BIOTECH CO LTD | 2015-09-02 | — | — | CN | disclosed |
| CN-104876904-A | Macrocyclic Compounds Useful As Pharmaceuticals | EISAI R&D MAN CO LTD | 2015-09-02 | — | — | CN | disclosed |
| US-20150238633-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. | 2015-08-27 | — | — | US | disclosed |
| EP-2427057-B1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN KETTERING INST CANCER (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2211885-B1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES | SEATTLE GENETICS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150203473-A1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2015-07-23 | — | — | US | disclosed |
| EP-2895466-A1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | Madrigal Pharmaceuticals, Inc. (US) | 2015-07-22 | — | — | EP | disclosed |
| US-9078931-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| WO-2015101622-A1 | NOVEL PYRAZOLYL-HETEROARYLAMIDES AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2015-07-09 | — | — | WO | disclosed |
| US-9073993-B2 | CD19 binding agents and uses thereof | SEATTLE GENETICS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| CN-104725628-A | Single functional branched polyethylene glycol containing degradable radical, preparation method and biorelevant substance of single functional branched polyethylene glycol | XIAMEN SINOPEG BIOTECH CO LTD | 2015-06-24 | — | — | CN | disclosed |
| US-9061994-B1 | Materials and methods useful to induce vacuolization, cell death, or a combination thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150164907-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150158853-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150152049-A1 | Materials And Methods Useful To Induce Vacuolization, Cell Death, Or A Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-06-04 | — | — | US | disclosed |
| US-9040555-B2 | Antifibrotic compounds and uses thereof | ANGION BIOMEDICA CORP. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9028796-B2 | Materials and methods useful to induce cell death via methuosis | THE UNIVERSITY OF TOLEDO (US) | 2015-05-12 | — | — | US | disclosed |
| US-9023871-B2 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-05-05 | — | — | US | disclosed |
| US-9017726-B2 | Biodegradable and thermosensitive poly(organophosphazene)-superparamagnetic nanoparticle complex, preparation method and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-04-28 | — | — | US | disclosed |
| US-20150111853-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME CORP. | 2015-04-23 | — | — | US | disclosed |
| CN-104530415-A | Hetero-functionalized Y-type polyethylene glycol derivative, preparation method and biologically related substance thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | disclosed |
| CN-104530417-A | Multifunctional H-type polyethylene glycol derivative and preparation method thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | disclosed |
| CN-104530413-A | Biologically related substances modified by multifunctional H-type polyethylene glycol derivative | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | disclosed |
| US-20150105380-A1 | METHODS AND USES OF COMPOUNDS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2015-04-16 | — | — | US | disclosed |
| US-9006421-B2 | Cephalosporin compositions and methods of manufacture | CUBIST PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150099766-A1 | Novel halogen-substituted compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20150094485-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES | CURIA SPAIN, S.A.U. (ES) | 2015-04-02 | — | — | US | disclosed |
| US-20150079114-A1 | DR5 LIGAND DRUG CONJUGATES | DAIICHI SANKYO CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-03-05 | — | — | US | disclosed |
| US-8968742-B2 | Antibody drug conjugates (ADC) that bind to 158P1D7 proteins | AGENSYS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8962857-B2 | Compounds for preparing immunological adjuvant | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8957056-B2 | Migrastatin analogs in the treatment of cancer | SLOAN-KETTERING INSTIUTE FOR CANCER RESEARCH (US) | 2015-02-17 | — | — | US | disclosed |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8946234-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2015-02-03 | — | — | US | disclosed |
| WO-2013112959-A9 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20150010549-A1 | Methods of Treating Amyotrophic Lateral Sclerosis | ANIDA PHARMA INC. (US) | 2015-01-08 | — | — | US | disclosed |
| WO-2015000825-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2015-01-08 | — | — | WO | disclosed |
| EP-2821394-A1 | Compounds with antibacterial activity | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2015-01-07 | — | — | EP | disclosed |
| EP-2814479-A1 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | Anida Pharma Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140371234-A1 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371240-A1 | NOVEL INSECTICIDAL AROMATIC AMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| EP-2807160-A1 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | Angion Biomedica Corp. (US) | 2014-12-03 | — | — | EP | disclosed |
| US-8901356-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2014-12-02 | — | — | US | disclosed |
| US-20140329871-A1 | SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140322128-A1 | Materials and Methods Useful to Induce Cell Death via Methuosis | THE UNIVERSITY OF TOLEDO (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322233-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | NAM SAMUEL S (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323739-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | Eisai R&D Management Co.. Ltd. (JP) | 2014-10-30 | — | — | US | disclosed |
| EP-2794573-A1 | NOVEL INSECTICIDAL AROMATIC AMIDES | Bayer Intellectual Property GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014170295-A1 | COMPOUNDS POTENTIATING THE ACTIVITY OF ANTIFUNGAL DRUGS | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2014-10-23 | — | — | WO | disclosed |
| EP-2792683-A1 | Compounds potentiating the activity of antifungal drugs | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2014-10-22 | — | — | EP | disclosed |
| US-8865752-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-20140309234-A1 | SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014154908-A1 | SELECTIVE ALKYLATION OF CYCLOPENTYL ALCOHOLS | CHEMO RESEARCH, S.L. (ES) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160360-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014152763-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CUBIST PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288136-A1 | METHODS AND USES OF CYTOCHROME P450 INHIBITORS | ANGION BIOMEDICA CORP (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140274999-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME CORP. | 2014-09-18 | — | — | US | disclosed |
| US-20140275591-A1 | NOVEL COMPOUNDS | AVANTI POLAR LIPIDS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140274958-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME LLC | 2014-09-18 | — | — | US | disclosed |
| EP-2776382-A1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2014-09-17 | — | — | EP | disclosed |
| US-8835693-B2 | Migrastatin analogs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-09-16 | — | — | US | disclosed |
| WO-2014135439-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2014-09-12 | — | — | WO | disclosed |
| WO-2013123290-A9 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | ANIDA PHARMA INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135437-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256816-A1 | Adamantyl Derivatives as Therapeutic Agents | WOMEN & INFANTS' HOSPITAL OF RHODE ISLAND (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256727-A1 | METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256780-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | ANGION BIOMEDICA CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2014134184-A1 | METHODS OF TREATING OTOTOXICITY | ANIDA PHARMA INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-8821850-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815226-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140234216-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | Merck & Cie (CH) | 2014-08-21 | — | — | US | disclosed |
| EP-2766364-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | Merck & Cie (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8808679-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2014122083-A1 | HALOGEN-SUBSTITUTED PYRAZOL DERIVATIVES AS PEST-CONTROL AGENTS | BAYER CROPSCIENCE AG (DE) | 2014-08-14 | — | — | WO | disclosed |
| US-20140213615-A1 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2014-07-31 | — | — | US | disclosed |
| US-8785600-B2 | Anti-GCC antibody molecules and related compositions and methods | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140193337-A1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2014-07-10 | — | — | US | disclosed |
| US-20140194601-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8772326-B2 | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity | Anigion Biomedica Corp. (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2014093960-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140171419-A1 | ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | ANGION BIOMEDICA CORP (US) | 2014-06-19 | — | — | US | disclosed |
| US-8754237-B2 | Bifunctional histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754236-B2 | Compounds for preparing immunological adjuvant | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-8754192-B2 | Compositions comprising homogeneously glycosylated erythropoietin | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-1805161-B1 | ISOMIGRASTATIN ANALOGS IN THE TREATMENT OF CANCER | SLOAN KETTERING INST CANCER (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20140121186-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | CHIMERIX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140107166-A1 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8691814-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20140088153-A1 | N-(3-CARBAMOYLPHENLY)-1H-PYRAZOLE-5-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF FOR CONTROLLING ANIMAL PESTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| WO-2014043706-A1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | MADRIGAL PHARMACEUTICALS, INC. (US) | 2014-03-20 | — | — | WO | disclosed |
| US-20140072586-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | SEATTLE GENETICS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140066476-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140051675-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140031289-A1 | POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-01-30 | — | — | US | disclosed |
| US-8637642-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | SEATTLE GENETICS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2014015137-A2 | COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | ANGION BIOMEDICA CORP. (US) | 2014-01-23 | — | — | WO | disclosed |
| EP-2686303-A1 | N-(3-CARBAMOYLPHENYL)-1H-PYRAZOLE-5-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF FOR CONTROLLING ANIMAL PESTS | Bayer Intellectual Property GmbH (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20140018401-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MERSANA THERAPEUTICS, INC. | 2014-01-16 | — | — | US | disclosed |
| WO-2014007361-A1 | METHOD OF FORMING PATTERN AND ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION FOR USE IN THE METHOD | FUJIFILM CORPORATION (JP) | 2014-01-09 | — | — | WO | disclosed |
| US-20140011844-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140012011-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-01-09 | — | — | US | disclosed |
| WO-2014008375-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-8614237-B2 | Benzofuran-4,5-diones as selective peptide deformylase inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-12-24 | — | — | US | disclosed |
| US-8614200-B2 | Compounds, compositions and methods for treating ocular conditions | CHIMERIX, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-8609092-B2 | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins | AGENSYS, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130331455-A1 | DEACETYLASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130323774-A1 | HOMOGENOUS AND FULLY GLYCOSYLATED HUMAN ERYTHROPOIETIN | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | MERSANA THERAPEUTICS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2664324-A1 | NANOCAPSULES WITH A POLYMER SHELL | Universidade De Santiago De Compostela (ES) | 2013-11-20 | — | — | EP | disclosed |
| EP-1572199-B1 | PYRAZOLE DERIVATIVES MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | ANGION BIOMEDICA CORP (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8586020-B2 | Poly(organophosphazene) composition for biomaterials | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | disclosed |
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP | 2013-11-14 | — | — | US | disclosed |
| US-8580834-B2 | Small molecule modulators of hepatocyte growth factor (scatter factor) activity | ANGION BIOMEDICA CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130288331-A1 | PEPTIDOMIMETIC COMPOUNDS AND RELATED METHODS | BURGESS KEVIN (US) | 2013-10-31 | — | — | US | disclosed |
| EP-1534269-B1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | GEN HOSPITAL CORP (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20130280282-A1 | DR5 LIGAND DRUG CONJUGATES | DAIICHI SANKYO CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-1709155-B1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CHESTERFORD ENTPR LTD (KY) | 2013-10-02 | — | — | EP | disclosed |
| US-8546419-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2629801-A2 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | Seattle Genetics, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8519170-B2 | Compounds for preparing immunological adjuvant | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| WO-2013123290-A1 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | ANIDA PHARMA INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-8513433-B2 | Small molecule inhibitors of PARP activity | ANGION BIOMEDICA CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513291-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130209496-A1 | Synergistic Effects Between Auristatin-Based Antibody Drug Conjugates And Inhibitors Of The PI3K-AKT mTOR Pathway | Seatle Genetics, Inc. (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2621526-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| WO-2013112959-A1 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2013-08-01 | — | — | WO | disclosed |
| US-20130189286-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | SEATTLE GENETICS (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190376-A1 | METHODS OF USE OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | ANGION BIOMEDICA CORP | 2013-07-25 | — | — | US | disclosed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | disclosed |
| WO-2013092522-A1 | NOVEL INSECTICIDAL AROMATIC AMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-8470329-B2 | Combination therapy with antibody-drug conjugates | SEATTLE GENETICS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2013085824-A1 | SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130136756-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | SEATTLE GENETICS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | disclosed |
| US-8440716-B2 | Deacetylase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130102643-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP | 2013-04-25 | — | — | US | disclosed |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| EP-2576544-A2 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | Angion Biomedica Corp. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8404088-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8399634-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| WO-2013034780-A2 | PROCESS FOR THE PREPARATION OF ESTETROL AND RELATED COMPOUNDS | CRYSTAL PHARMA, S.A.U. (ES) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013026842-A1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2013-02-28 | — | — | WO | disclosed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | disclosed |
| US-8383758-B2 | Biodegradable polyketal polymers and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2013024035-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | Merck & Cie (CH) | 2013-02-21 | — | — | WO | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| US-20130035321-A1 | COMPOUNDS FOR THE TREATMENT OF OCULAR CANCER | ANALYTICON DISCOVERY GMBH (DE) | 2013-02-07 | — | — | US | disclosed |
| EP-1664341-B1 | SIZE-CONTROLLED MACROMOLECULE | POSCO (KR) | 2013-01-30 | — | — | EP | disclosed |
| US-8361442-B2 | Oxime conjugates and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130022627-A1 | Combination Therapy With Antibody-Drug Conjugates | SEATTLE GENETICS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8357723-B2 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited and Apparao Satyam (IN) | 2013-01-22 | — | — | US | disclosed |
| US-20130018103-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8354455-B2 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited and Apparao Satyam (IN) | 2013-01-15 | — | — | US | disclosed |
| US-8349901-B2 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited and Apparao Satyam (IN) | 2013-01-08 | — | — | US | disclosed |
| US-20130004455-A1 | POLY(ORGANOPHOSPHAZENE) COMPOSITION FOR BIOMATERIALS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-01-03 | — | — | US | disclosed |
| EP-2540764-A2 | Poly(organophosphazene) composition for biomaterials | Korea Institute of Science and Technology (KR) | 2013-01-02 | — | — | EP | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-8329742-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8324284-B2 | Migrastatin analogs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120294853-A1 | CD19 Binding Agents and Uses Thereof | SEATTLE GENETICS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8313771-B2 | Phosphazene hydrogels with chemical corss-link, preparation method thereof and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-20 | — | — | US | disclosed |
| US-20120289535-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8309093-B2 | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins | AGENSYS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8304451-B2 | Histone deacetylase and tubulin deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-11-06 | — | — | US | disclosed |
| WO-2012145069-A2 | MATERIALS AND METHODS USEFUL TO INDUCE CELL DEATH VIA METHUOSIS | THE UNIVERSITY OF TOLEDO (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012126766-A1 | N-(3-CARBAMOYLPHENYL)-1H-PYRAZOLE-5-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF FOR CONTROLLING ANIMAL PESTS | BAYER CROPSCIENCE AG (DE) | 2012-09-27 | — | — | WO | disclosed |
| US-20120238766-A1 | ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120232298-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | FANG FRANCIS G (US) | 2012-09-13 | — | — | US | disclosed |
| US-8263083-B2 | Combination therapy with antibody-drug conjugates | SEATTLE GENETICS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2490720-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | Millennium Pharmaceuticals, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8247427-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-21 | — | — | US | disclosed |
| US-8242252-B2 | CD19 binding agents and uses thereof | SEATTLE GENETICS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120190716-A1 | METHODS AND USES OF CYTOCHROME P450 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-26 | — | — | US | disclosed |
| US-20120190668-A1 | ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLEUCLE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-26 | — | — | US | disclosed |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| US-8222423-B2 | Bifunctional histone deacetylase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120165295-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | CHIMERIX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8202911-B2 | Migrastatin analog compositions and uses thereof | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8198474-B2 | Compounds for preparing immunological adjuvant | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| WO-2012074980-A2 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISORDERS AND LIVER DISORDERS USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142911-A1 | SYNTHESIS OF TTX INTERMEDIATES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2012-06-07 | — | — | US | disclosed |
| US-8193270-B2 | Method of making composites and nanocomposites | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193177-B2 | Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases | ANGION BIOMEDICA CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8188141-B2 | Isomigrastatin analogs in the treatment of cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-05-29 | — | — | US | disclosed |
| US-8183351-B2 | Avermectin derivatives | BAYER CROPSCIENCE AG (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20120121517-A1 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF | Korean Institute of Science and Technology of Seoul, Republic of Korea | 2012-05-17 | — | — | US | disclosed |
| US-8178579-B2 | Histone deacetylase inhibitors; anticancer agents; antiprotozoa agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2012054748-A2 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEATTLE GENETICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| EP-2441758-A1 | SYNTHESIS OF TTX INTERMEDIATES | Consejo Superior De Investigaciones Científicas (ES) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012047724-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120078028-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | SEAGEN INC. | 2012-03-29 | — | — | US | disclosed |
| EP-1682537-B1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-03-22 | — | — | US | disclosed |
| US-8137509-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral brønsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2427057-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2012-03-14 | — | — | EP | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20120035154-A1 | Modulators of Cellular Adhesion | SARcode Bioscience, Inc. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120027680-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
| US-8101164-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2403524-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | Agensys, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20120004255-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110312088-A1 | CD19 BINDING AGENTS AND USES THEREOF | SEATTLE GENETICS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110301181-A1 | halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2011-12-08 | — | — | US | disclosed |
| WO-2011153192-A2 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2011-12-08 | — | — | WO | disclosed |
| US-8071617-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110281916-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110274695-A1 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | PIRAMAL LIFE SCIENCES LIMITED | 2011-11-10 | — | — | US | disclosed |
| US-20110275700-A1 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110269722-A1 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | Piramal Life Science Limited | 2011-11-03 | — | — | US | disclosed |
| US-20110269709-A1 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | PIRAMAL LIFE SCIENCES LIMITED | 2011-11-03 | — | — | US | disclosed |
| US-20110263693-A1 | CELASTROL, GEDUNIN, AND DERIVATIVES THEREOF AS HSP90 INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263653-A1 | MIGRASTATIN ANALOG COMPOSITIONS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-27 | — | — | US | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| EP-2374454-A1 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | Eisai R&D Management Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-8030459-B2 | Oxime conjugates and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110237633-A1 | SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-09-29 | — | — | US | disclosed |
| US-20110230407-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-09-22 | — | — | US | disclosed |
| US-20110217321-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20110207947-A1 | METHOD FOR OBTAINING ZARAGOZIC ACID AND DERIVATIVES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2011-08-25 | — | — | US | disclosed |
| EP-2352723-A2 | HALOGEN-SUBSTITUTED COMPOUNDS USED AS PESTICIDES | Bayer CropScience AG (DE) | 2011-08-10 | — | — | EP | disclosed |
| US-7989626-B2 | Modulators of cellular adhesion | SAR code Corporation (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110184038-A1 | METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110172303-A1 | DEACETYLASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| EP-2341140-A1 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-7968687-B2 | CD19 binding agents and uses thereof | SEATTLE GENETICS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2336315-A2 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-06-22 | — | — | EP | disclosed |
| EP-1989193-B1 | PROCESS FOR OBTAINING ENANTIOMERS OF DULOXETINE PRECURSORS | ESTEVE LABOR DR (ES) | 2011-06-22 | — | — | EP | disclosed |
| US-20110144101-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| WO-2011068876-A1 | COMPOUNDS FOR THE TREATMENT OF OCULAR CANCER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-06-09 | — | — | WO | disclosed |
| US-7951898-B2 | Biodegradable polyketal polymers and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110124669-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2321264-A2 | DEACETYLASE INHIBITORS AND USES THEREOF | President and Fellows of Harvard College (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7943800-B2 | Migrastatin analogs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-05-17 | — | — | US | disclosed |
| US-20110110936-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | DAUN JANE | 2011-05-05 | — | — | US | disclosed |
| EP-1667726-B1 | POLYACETAL DRUG CONJUGATES AS RELEASE SYSTEM | GEN HOSPITAL CORP (US) | 2011-05-04 | — | — | EP | disclosed |
| WO-2011050242-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110098304-A1 | Small molecule inhibitors of PARP activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-28 | — | — | US | disclosed |
| US-7932294-B2 | Prodrugs containing novel bio-cleavable linkers | APPARAO SATYAM (IN) | 2011-04-26 | — | — | US | disclosed |
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| EP-2311841-A1 | METHOD FOR OBTAINING ZARAGOZIC ACID AND DERIVATIVES THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2011-04-20 | — | — | EP | disclosed |
| US-7928122-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2308861-A1 | Macrocyclic compounds useful as pharmaceuticals | Eisai R&D Management Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7915306-B2 | For therapy of inflammatory or autoimmune disorders | EISAI CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20110070248-A1 | DR5 LIGAND DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110065786-A1 | SYNTHESIS OF ROCAGLAMIDE NATURAL PRODUCTS VIA PHOTOCHEMICAL GENERATION OF OXIDOPYRYLIUM SPECIES | TRUSTEES OF BOSTON UNIVERSITY | 2011-03-17 | — | — | US | disclosed |
| US-7906633-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20110059010-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2292628-A2 | Compounds for preparing immunological adjuvant | Eisai R&D Management Co., Ltd. (JP) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292227-A2 | Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity | Angion Biomedica Corp. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-7879898-B1 | treating a chronic obstructive pulmonary disease using modulators of HGF/SF activity; for example, 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one; emphysema | ANGION BIOMEDICA CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| WO-2011011519-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OCULAR CONDITIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-7868002-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| WO-2011002520-A2 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2011-01-06 | — | — | WO | disclosed |
| EP-2269657-A2 | Prodrugs containing novel bio-cleavable linkers | Piramal Life Sciences Limited (IN) | 2011-01-05 | — | — | EP | disclosed |
| US-20100330107-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | AGENSYS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2266623-A2 | Prodrugs containing novel bio-cleavable linkers | Piramal Life Sciences Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266622-A2 | Prodrugs containing novel bio-cleavable linkers | Piramal Life Sciences Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266625-A2 | Prodrugs Containing Novel Bio-Cleavable Linkers | Piramal Life Sciences Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010141690-A2 | INDANE ANALOGS AND USE AS PHARMACEUTICAL AGENTS AND PROCESS OF MAKING | DARA BIOSCIENCES, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| EP-1957644-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20100297155-A1 | PHOSPHAZENE HYDROGELS WITH CHEMICAL CORSS-LINK, PREPARATION METHOD THEREOF AND USE THEREOF | DECA ITALIA S.R.L. (IT) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135520-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100297079-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7838619-B2 | Biodegradable polyketal polymers and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2010-11-23 | — | — | US | disclosed |
| WO-2010129049-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-11-11 | — | — | WO | disclosed |
| US-7824687-B2 | Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100267827-A1 | PHENYL-PRENYL-ETHER DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-10-21 | — | — | US | disclosed |
| US-7816544-B2 | Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species | TRUSTEES OF BOSTON UNIVERSITY (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100256117-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | ANGION BIOMEDICA CORP. | 2010-10-07 | — | — | US | disclosed |
| WO-2010111018-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | AGENSYS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-7799827-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20100234312-A1 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-7790743-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790150-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-7786217-B2 | formed by contacting an end functionalized polyolefins with living organometallic polymers in the presence of an initiator, to form block polymers having heat and oxidation reistance, used as medical equipment | UNIVERSITY OF MASSACHUSETTS LOWELL (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100215671-A1 | Combination Therapy With Antibody-Drug Conjugates | SEAGEN INC. | 2010-08-26 | — | — | US | disclosed |
| EP-1789091-B1 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | PIRAMAL LIFE SCIENCES LTD (IN) | 2010-08-25 | — | — | EP | disclosed |
| EP-2214667-A2 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | Angion Biomedica Corp. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100197951-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2211904-A2 | CD19 BINDING AGENTS AND USES THEREOF | Seattle Genetics, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-2054427-B1 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-07-14 | — | — | EP | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2010068247-A1 | CARDENOLIDES FOR THE TREATMENT OF OCULAR CANCER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100152206-A1 | Bicyclic Dihydropyrimidines and Uses Thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-06-17 | — | — | US | disclosed |
| US-20100150832-A1 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010051926-A2 | NEW HALOGEN-SUBSTITUTED BONDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-05-14 | — | — | WO | disclosed |
| EP-2184273-A1 | Halogen substituted compounds as pesticides | Bayer CropScience AG (DE) | 2010-05-12 | — | — | EP | disclosed |
| US-20100093842-A1 | Laulimalide Analogs and Uses Thereof | EISAI CO. LTD. | 2010-04-15 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| US-7683200-B2 | Compounds for preparing immunological adjuvant | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2158254-A1 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2010-03-03 | — | — | EP | disclosed |
| EP-2155806-A1 | PHOSPHAZENE HYDROGELS WITH CHEMICAL CORSS -LINK, PREPARATION METHOD THEREOF AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2010-02-24 | — | — | EP | disclosed |
| US-20100041665-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| WO-2010011296-A2 | DEACETYLASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-01-28 | — | — | WO | disclosed |
| US-7648978-B2 | Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone | ANGION BIOMEDICA CORP. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20100004234-A1 | SPECIFIC KINASE INHIBITORS | KOSAN BIOSCIENCES INCORPORATED | 2010-01-07 | — | — | US | disclosed |
| US-7642284-B2 | Luminacin analogs and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-7635750-B2 | Reacting a peptide acyl donor comprising a peptidic backbone made up of two or more amino acids with a peptide amine acceptor under reducing reaction conditions employing an excess of a reducing agent; | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-17 | — | — | US | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-26 | — | — | US | disclosed |
| WO-2009141096-A1 | SUBSTITUTED SPIRO-ISOXAZOLINES | BAYER CROPSCIENCE AG (DE) | 2009-11-26 | — | — | WO | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| US-20090247771-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF DULOXETINE PRECURSORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-01 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585997-B2 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CHESTERFORD ENTERPRISES LIMITED (KY) | 2009-09-08 | — | — | US | disclosed |
| EP-2010556-A4 | HOMOGENEOUS ERYTHROPOIETIN AND OTHER PEPTIDES AND PROTEINS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | SLOAN KETTERING INST CANCER (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| EP-2075011-A2 | Prodrugs Containing Bio-Cleavable Linkers | Piramal Life Sciences Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| US-20090136526-A1 | CD19 Binding Agents and Uses Thereof | SEATTLE GENETICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090131406-A1 | CROPWELLLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | BAYER CROPSCIENCE AG (DE) | 2009-05-21 | — | — | US | disclosed |
| US-20090124662-A1 | Migrastatin analogs in the treatment of cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2009-05-14 | — | — | US | disclosed |
| US-7531181-B2 | Gp120 specific antigens and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| EP-2054427-A2 | AVERMECTIN DERIVATIVES | Bayer CropScience AG (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| WO-2009054952-A2 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-7524883-B2 | Eponemycin and epoxomicin analogs and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| WO-2009052431-A2 | CD19 BINDING AGENTS AND USES THEREOF | SEATTLE GENETICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090054488-A1 | Isomigrastatin Analogs In The Treatment Of Cancer | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-26 | — | — | US | disclosed |
| US-20090047348-A1 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-02-19 | — | — | US | disclosed |
| EP-2019674-A2 | HISTONE DEACETYLASE AND TUBULIN DEACETYLASE INHIBITORS | The President and Fellows of Harvard College (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-2010556-A2 | HOMOGENEOUS ERYTHROPOIETIN AND OTHER PEPTIDES AND PROTEINS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | Sloan-Kettering Institute for Cancer Research (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008153277-A1 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153278-A1 | PHOSPHAZENE HYDROGELS WITH CHEMICAL CORSS -LINK, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
| EP-1991247-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | The President and Fellows of Harvard College (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20080281094-A1 | Regioselective Functionalisation and Protection of Spirolactams | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-11-13 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| WO-2008127695-A1 | ORGANOMETALLIC-POLYISOMONOOLEFIN BLOCK COPOLYMERS | UNIVERSITY OF MASSACHUSETTS LOWELL (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255330-A1 | Organometallic-Polyisomonoolefin Block Copolymers | UNIVERSITY OF MASSACHUSETTS LOWELL | 2008-10-16 | — | — | US | disclosed |
| US-20080249320-A1 | Luminacin analogs and uses thereof | EISAI R&D MANAGEMENT CO. LTD. | 2008-10-09 | — | — | US | disclosed |
| EP-1468036-B1 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | GEN HOSPITAL CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008103593-A1 | POWDER COATING FLUOROPOLYMER COMPOSITIONS WITH DEPROTECTABLE AROMATIC MATERIALS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-08-28 | — | — | WO | disclosed |
| EP-1956024-A1 | 1-Azaspiro[3.5]nonan-2-ona-5,7-carbolact one and 5,7-protected-1-azaspiro[3.5]nonan-2-one derivatives and their use as intermediates in the synthesis of TTX | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008091349-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080177093-A1 | Synthesis of Rocaglamide Natural Products Via Photochemical Generation of Oxidopyrylium Species | TRUSTEES OF BOSTON UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| WO-2008080986-A1 | FURAN DERIVATIVES, METHOD OF SYNTHESIS AND USES THEREOF | NEUROPHARMA, S.A. (ES) | 2008-07-10 | — | — | WO | disclosed |
| EP-1939192-A1 | Cyclopentanone derivatives, method of synthesis and uses thereof | Neuropharma S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
| EP-1474425-B9 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939191-A1 | Furan derivatives, method of synthesis and uses thereof | Neuropharma S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080103137-A1 | Deazapurines and uses thereof | EISAI CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-20080095810-A1 | Nanoparticles Of Chitosan And Polyethyleneglycol As A System For The Administration Of Biologically-Active Molecules | ADVANCED IN VITRO CELL TECHNOLOGIES, S.L. (ES) | 2008-04-24 | — | — | US | disclosed |
| EP-1910387-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | Eisai Co., Ltd (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1896480-A1 | CRIPOWELLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | Bayer CropScience Aktiengesellschaft (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080045726-A1 | Spirolactams and Their Synthesis | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-02-21 | — | — | US | disclosed |
| WO-2008019784-A2 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2008-02-21 | — | — | WO | disclosed |
| EP-1889840-A1 | Rearrangement of spirolactams | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-02-20 | — | — | EP | disclosed |
| EP-1886990-A1 | Phenyl-prenyl-ether derivatives for the treatment of cognitive neurodegenerative or neuronal diseases or disorders | Neuropharma S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
| EP-1882692-A1 | Dimethano-[1,3]dioxocino[6,5-D]pyrimidine-spiro derivatives of tetrodotoxin, process for their synthesis and uses thereof in the treatment of pain | Wex Pharmaceuticals Inc. (CA) | 2008-01-30 | — | — | EP | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1864653-A2 | NANOPARTICLES OF CHITOSAN AND POLYETHYLENEGLYCOL AS A SYSTEM FOR THE ADMINISTRATION OF BIOLOGICALLY-ACTIVE MOLECULES | Advanced in Vitro Cell Technologies, S.L. (ES) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007139749-A2 | ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-7297788-B2 | Regioselective hydroxylation, functionalisation and protection of spirolactams | LABORATORIOS DEL DR. ESTEVE. S.A. (ES) | 2007-11-20 | — | — | US | disclosed |
| WO-2007130429-A2 | HISTONE DEACETYLASE AND TUBULIN DEACETYLASE INHIBITORS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-11-15 | — | — | WO | disclosed |
| EP-1709155-A4 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | KASHFI KHOSROW (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007120614-A2 | HOMOGENEOUS ERYTHROPOIETIN AND OTHER PEPTIDES AND PROTEINS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007117466-A2 | CELASTROL, GEDUNIN, AND DERIVATIVES THEREOF AS HSP90 INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-10-18 | — | — | WO | disclosed |
| US-7265112-B2 | Small molecule modulators of hepatocyte growth factor (scatter factor) activity | ANGION BIOMEDICA CORP. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1826204-A1 | Process for obtaining enantiomers of duloxetine precursors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-08-29 | — | — | EP | disclosed |
| US-20070190018-A1 | Dual phase drug release system | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-16 | — | — | US | disclosed |
| US-7250437-B2 | Small molecule modulators of hepatocyte growth factor (scatter factor) activity | ANGION BIOMEDICA CORP. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070173636-A1 | Method for preparing polyfunctionalized peptides and/or proteins via native chemical ligation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-26 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1799651-A2 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | Angion Biomedica Corp. (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1789091-A2 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | Nicholas Piramal India Limited (IN) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007054517-A1 | SYNTESIS OF TETRODOTOXIN , ITS ANALOGUES AND INTERMEDIATES THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-18 | — | — | WO | disclosed |
| EP-1785427-A1 | Syntesis of tetrodotoxin, its analogues and intermediates thereof | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-16 | — | — | EP | disclosed |
| US-20070082875-A1 | toll-like receptor-4 agonists; vaccines | EISAI CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| EP-1771410-A1 | SPIROLACTAMS AND THEIR SYNTHESIS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-04-11 | — | — | EP | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192976-B2 | 3-substituted pyrazoles; cell proliferation and angiogenesis promoters; antiapoptotosis and antifibrosis activity | ANGION BIOMEDICA CORPORATION (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070037852-A1 | Migrastatin analogs and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-02-15 | — | — | US | disclosed |
| US-20070037783-A1 | Migrastatin analogs and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-02-15 | — | — | US | disclosed |
| EP-1747197-A1 | REGIOSELECTIVE FUNCTIONALISATION AND PROTECTION OF SPIROLACTAMS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-31 | — | — | EP | disclosed |
| WO-2007005583-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | EISAI CO., LTD. (JP) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006136309-A1 | CRIPOWELLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
| US-7132568-B2 | Aspartyl protease inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060247448-A1 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20060229432-A1 | Gp120 specific antigens and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2006-10-12 | — | — | US | disclosed |
| EP-1709155-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | Kashfi, Khosrow (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1707566-A1 | Deazapurines and uses thereof | Eisai Co., Ltd. (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-7115652-B2 | Aspartyl protease inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060205674-A2 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | NICHOLAS PIRAMAL INDIA LTD. (IN) | 2006-09-14 | — | — | US | disclosed |
| US-7101891-B2 | Compounds and pharmaceutical compositions for inhibiting MRP1 | ELI LILLY AND COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060160999-A1 | Reagents and methods for preparing lps antagonist b1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20060154872-A1 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| US-20060148778-A1 | Ultraviolet radiation absorbers; such as 1 azaspiro(3,5)nona-5,8-dione derivative substituted in first position with oxy, thio or carbonyl group | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | US | disclosed |
| EP-1676836-A1 | Regioselective hydroxylation, functionalisation and protection of spirolactams II | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-05 | — | — | EP | disclosed |
| US-7064131-B2 | Compounds and methods for inhibiting MRP1 | ELI LILLY AND COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| US-7064211-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20060128867-A1 | Method of making composites and nanocomposites | 3M INNOVATIVE PROPERTIES COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1664341-A2 | SIZE-CONTROLLED MACROMOLECULE | Posco (KR) | 2006-06-07 | — | — | EP | disclosed |
| US-20060116365-A1 | Small molecule modulators of cytokine activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-01 | — | — | US | disclosed |
| EP-1474425-B1 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-7037921-B2 | Useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by multidrug resistance protein MRP1 | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060079494-A1 | Specific kinase inhibitors | KOSAN BIOSCIENCES INCORPORATED | 2006-04-13 | — | — | US | disclosed |
| EP-1644322-A1 | ASPARTYL PROTEASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2006036981-A2 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069230-A1 | Biodegradable polyketal polymers and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION | 2006-03-30 | — | — | US | disclosed |
| US-20060058513-A1 | Oxime conjugates and methods for their formation and use | ENERGY, UNITED STATES DEPARTMENT OF | 2006-03-16 | — | — | US | disclosed |
| WO-2006027711-A2 | PRODRUGS AND CODRUGS CONTAINING BIO- CLEAVABLE DISULFIDE LINKERS | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-03-16 | — | — | WO | disclosed |
| US-20060046967-A1 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited (IN) | 2006-03-02 | — | — | US | disclosed |
| US-20060045846-A1 | Reagents and methods for labeling terminal olefins | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-03-02 | — | — | US | disclosed |
| WO-2006017180-A2 | GLYCOPEPTIDE DIMERS AND USES THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| EP-1140064-B1 | ORAL ADMINISTRATION OF TAXOID DERIVATIVES | AVENTIS PHARMA SA (FR) | 2006-02-15 | — | — | EP | disclosed |
| US-20060019951-A1 | Vacuolins | CBR INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2006-01-26 | — | — | US | disclosed |
| EP-1224189-B1 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050287596-A9 | Novel ligands and libraries of ligands | SUNESIS PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050267098-A1 | Modulators of cellular adhesion | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2005-12-01 | — | — | US | disclosed |
| EP-1392702-B1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050261492-A1 | Regioselective hydroxylation, functionalisation and protection of spirolactams | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2005-11-24 | — | — | US | disclosed |
| EP-1598336-A1 | Regioselective hydroxylation, functionalisation and protection of spirolactams | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005108357-A1 | REGIOSELECTIVE FUNCTIONALISATION AND PROTECTION OF SPIROLACTAMS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108356-A1 | SPIROLACTAMS AND THEIR SYNTHESIS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-11-17 | — | — | WO | disclosed |
| US-20050239870-A1 | Prevention of restenosis of blood vessels after trauma, angioplasty or stenting; aminoalkylamide, piperidine-, indole-, or pyrrole-amide derivatives; anticarcinogenic agents | Eisai Co., Ltd., (JP) | 2005-10-27 | — | — | US | disclosed |
| US-20050228039-A1 | Luminacin analogs and uses thereof | UCB PHARMA, S.A. (BE) | 2005-10-13 | — | — | US | disclosed |
| WO-2005092876-A1 | SYNTHESIS OF ROCAGLAMIDE NATURAL PRODUCTS VIA PHOTOCHEMICAL GENERATION OF OXIDOPYRYLIUM SPECIES | TRUSTEES OF BOSTON UNIVERSITY (US) | 2005-10-06 | — | — | WO | disclosed |
| US-20050192331-A1 | Administering 3-substituted pyrazoles for therapy of fibrotic liver disease; hepatic isehemia-reperfusion injury; cerebral infarction; ischemic heart disease; renal disease; lung (pulmonary) fibrosis; liver fibrosis associated with hepatitis C, hepatitis B, delta hepatitis, chronic alcoholism | ANGION BIOMEDICA CORP. | 2005-09-01 | — | — | US | disclosed |
| US-20050182134-A1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CONVERSANT INTELLECTUAL PROPERTY MANAGEMENT INC. (CA) | 2005-08-18 | — | — | US | disclosed |
| WO-2005065361-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | KASHFI KHOSROW (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1385852-B1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005056572-A2 | CLUSTERED MULTI-ANTIGENIC CARBOHYDRATE CONSTRUCTS, METHODS FOR THEIR PREPARATION AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050124649-A1 | Deazapurines and uses thereof | EISAI CO., LTD (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050113369-A1 | Pyrrazoles connnected to a carbocyclic ring by a vinylene, butadienylene or hexatrienylene bridge, e.g. 3(5)-[2-(2-chloro-5-trifluoromethylphenyl)vinyl]-1H-pyrazole; compounds exhibit antifibrotic and antiapoptotic activities | ANGION BIOMEDICA CORP. | 2005-05-26 | — | — | US | disclosed |
| US-20050101781-A1 | Eponemycin and epoxomicin analogs and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1458702-B1 | LUMINACIN ANALOGS AND USES THEREOF | EISAI CO LTD (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-6878743-B2 | Small molecule inhibitors of caspases | SUNESIS PHARMACEUTICALS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| WO-2005026191-A2 | SIZE-CONTROLLED MACROMOLECULE | POSCO (KR) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005023792-A2 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO. LTD. (JP) | 2005-03-17 | — | — | WO | disclosed |
| EP-1412346-B1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2005-03-09 | — | — | EP | disclosed |
| US-20050037413-A1 | functionalized substrates bound to layers of dendrimers and to target-specific ligands, used in combinatorial chemistry, protein, nucleic acid or nucleic acid/peptide hybridization detection; medical diagnosis | POSCO (KR) | 2005-02-17 | — | — | US | disclosed |
| WO-2005005374-A1 | ASPARTYL PROTEASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040235880-A1 | Compounds and methods for inhibiting mrp1 | LANDER PETER AMBROSE (US) | 2004-11-25 | — | — | US | disclosed |
| US-20040229819-A1 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224936-A1 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2004-11-11 | — | — | US | disclosed |
| US-20040208884-A1 | Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-10-21 | — | — | US | disclosed |
| EP-1468036-A2 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040186127-A1 | Novel deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| EP-1458702-A1 | LUMINACIN ANALOGS AND USES THEREOF | Eisai Co., Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20040180882-A1 | 3-substituted pyrazoles; cell proliferation and angiogenesis promoters; antiapoptotosis and antifibrosis activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-09-16 | — | — | US | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| US-20040147454-A1 | Aspartyl protease inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040132782-A1 | Aspartyl protease inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2004-07-08 | — | — | US | disclosed |
| US-20040116460-A1 | Compounds and pharmaceutical compositions for inhibiting mrp1 | COHEN JEFFREY DANIEL (US) | 2004-06-17 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1421063-A1 | DISULFIDE AND THIOSULFONATE LIGANDS AND LIBRARIES COMPRISING THESE LIGANDS | Sunesis Pharmaceuticals, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040097507-A1 | Compounds and methods for inhibiting mrp1 | BONJOUKLIAN ROSANNE (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1412346-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | Bayer CropScience AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | BONJOUKLIAN ROSANNE (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
| EP-1392702-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1392701-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1385852-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6686376-B2 | INHIBITING A RESISTANT NEOPLASM, OR A NEOPLASM SUSCEPTIBLE TO RESISTANCE IN A MAMMAL WHICH COMPRISES ADMINISTERING COMPOUND OF INVENTION | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-20040010005-A1 | Stereoselective process for preparing cylcohexyl amine derivatives | BARNETT CHARLES JACKSON (US) | 2004-01-15 | — | — | US | disclosed |
| US-6673809-B2 | INHIBITING RESISTANT NEOPLASM, OR NEOPLASM SUSCEPTIBLE TO RESISTANCE | ELI LILLY AND COMPANY | 2004-01-06 | — | — | US | disclosed |
| US-6670373-B1 | Inhibiting resistant neoplasms where the resistance is conferred by multidrug resistance protein; N-3,4,5-trimethoxyphenyl-3-(3-azidomethyl-isoxazolo(4,5-c) -1,2-dihydro-6-chloro-quinolin-2-on-1-yl)phenylacetamide | ELI LILLY AND COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030232854-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| US-20030229132-A1 | Small molecule modulators of apoptosis | SUNESIS PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030216425-A1 | Tricyclic compounds as mrp1-inhibitors | ELI LILLY AND COMPANY | 2003-11-20 | — | — | US | disclosed |
| WO-2003059988-A2 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003057685-A1 | LUMINACIN ANALOGS AND USES THEREOF | EISAI CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
| EP-1322652-A1 | STEREOSELECTIVE PROCESS FOR PREPARING CYCLOHEXYL AMINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030114447-A1 | Small molecule inhibitors of caspases | SUNESIS PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-1301518-A1 | TRICYCLIC COMPOUNDS AS MRP1-INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1296953-A2 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2003024955-A2 | SMALL MOLECULE INHIBITORS OF CASPASES | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| EP-0979076-A4 | INTERMEDIATES AND PROCESSES FOR PREPARING BENZO b]THIOPHENES | LILLY CO ELI (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2003014072-A1 | DISULFIDE AND THIOSULFONATE LIGANDS AND LIBRARIES COMPRISING THESE LIGANDS | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| EP-1032565-B1 | METHOD FOR PREPARING DERIVATIVES OF THE TAXOID CLASS | AVENTIS PHARMA SA (FR) | 2003-02-19 | — | — | EP | disclosed |
| WO-2003010155-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-02-06 | — | — | WO | disclosed |
| US-20030013125-A1 | Novel ligands and libraries of ligands | BRAISTED ANDREW C (US) | 2003-01-16 | — | — | US | disclosed |
| WO-2002081482-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002081480-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002081481-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-1224189-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-0979075-A4 | A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO b]THIOPHENES | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| US-20020082291-A1 | NEW USE OF TAXOID DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2002-06-27 | — | — | US | disclosed |
| US-6403634-B1 | FOR TREATING ABNORMAL CELL PROLIFERATION | AVENTIS PHARMA S.A. (FR) | 2002-06-11 | — | — | US | disclosed |
| US-6369070-B1 | Methods for inhibiting mrp1 | ELI LILLY AND COMPANY | 2002-04-09 | — | — | US | disclosed |
| WO-2002024705-A1 | STEREOSELECTIVE PROCESS FOR PREPARING CYCLOHEXYL AMINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| US-6346543-B1 | ADMINISTERING BACCATIN DERIVATIVE AS ANTICARCINOGENIC AGENT | AVENTIS PHARMA S.A. (FR) | 2002-02-12 | — | — | US | disclosed |
| WO-2002000624-A2 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001096346-A1 | TRICYCLIC COMPOUNDS AS MRP1-INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1067928-A4 | METHODS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1140064-A2 | ORAL ADMINISTRATION OF TAXOID DERIVATIVES | Aventis Pharma S.A. (FR) | 2001-10-10 | — | — | EP | disclosed |
| US-6291484-B1 | TREATMENT OF THE VARIOUS MEDICAL CONDITIONS ASSOCIATED WITH POSTMENOPAUSAL SYNDROME | ELI LILLY AND COMPANY | 2001-09-18 | — | — | US | disclosed |
| EP-1109547-A1 | NEW USE OF TAXOID DERIVATIVES | Aventis Pharma S.A. (FR) | 2001-06-27 | — | — | EP | disclosed |
| EP-1105119-A2 | NEW USE OF TAXOID DERIVATIVES | Aventis Pharma S.A. (FR) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001027116-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1067928-A1 | METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1032565-A1 | METHOD FOR PREPARING DERIVATIVES OF THE TAXOID CLASS | Aventis Pharma S.A. (FR) | 2000-09-06 | — | — | EP | disclosed |
| US-6107346-A | ADMINISTERING AND AROMATIC KETONE COMPOUND | ELI LILLY AND COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| WO-2000041482-A2 | ORAL ADMINISTRATION OF TAXOID DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2000-07-20 | — | — | WO | disclosed |
| EP-1020188-A1 | New use of taxoid derivatives | Aventis Pharma S.A. (FR) | 2000-07-19 | — | — | EP | disclosed |
| US-6090843-A | POSTMENOPAUSE DISEASES; ESTROGEN SENSITIVITY; BONE DISORDERS | ELI LILLY AND COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| US-6090949-A | Processes for preparing benzothiophenes | ELI LILLY AND COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| US-6075146-A | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals | ELI LILLY AND COMPANY (US) | 2000-06-13 | — | — | US | disclosed |
| US-6043360-A | Intermediates and a process for preparing benzo[B]thiophenes | ELI LILLY AND COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| WO-2000010547-A2 | NEW USE OF TAXOID DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2000-03-02 | — | — | WO | disclosed |
| EP-0982028-A1 | New use of taxoid derivatives | Aventis Pharma S.A. (FR) | 2000-03-01 | — | — | EP | disclosed |
| EP-0982027-A1 | Taxoid derivatives for treating abnormal cell proliferation of the brain | Aventis Pharma S.A. (FR) | 2000-03-01 | — | — | EP | disclosed |
| WO-2000009120-A1 | NEW USE OF TAXOID DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2000-02-24 | — | — | WO | disclosed |
| EP-0979075-A1 | A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO b]THIOPHENES | ELI LILLY AND COMPANY (US) | 2000-02-16 | — | — | EP | disclosed |
| EP-0979076-A1 | INTERMEDIATES AND PROCESSES FOR PREPARING BENZO b]THIOPHENES | ELI LILLY AND COMPANY (US) | 2000-02-16 | — | — | EP | disclosed |
| US-6025495-A | Regioselective alkylation process for preparing substituted benzo[b]thiophenes | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| US-6018056-A | Intermediates and processes for preparing benzo (b) thiophenes | ELI LILLY AND COMPANY (US) | 2000-01-25 | — | — | US | disclosed |
| WO-1999051228-A1 | METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 1999-10-14 | — | — | WO | disclosed |
| US-5962705-A | ALKYLATION | RHONE-POULENC RORER S.A. (FR) | 1999-10-05 | — | — | US | disclosed |
| US-5908859-A | ESPECIALLY HYPERCHOLESTEROLEMIA | ELI LILLY AND COMPANY (US) | 1999-06-01 | — | — | US | disclosed |
| WO-1999025704-A1 | METHOD FOR PREPARING DERIVATIVES OF THE TAXOID CLASS | AVENTIS PHARMA S.A. (FR) | 1999-05-27 | — | — | WO | disclosed |
| EP-0902025-A2 | Benzothiophenes for treatment of estrogen related conditions | ELI LILLY AND COMPANY (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0897918-A1 | Benzothiophene derivatives and their use as pharmaceutically active agents | ELI LILLY AND COMPANY (US) | 1999-02-24 | — | — | EP | disclosed |
| EP-0897903-A2 | Ketone-derivatives of indene, dihydronaphthalene or naphthalene compounds for the treatment of hyperlipidemia | ELI LILLY AND COMPANY (US) | 1999-02-24 | — | — | EP | disclosed |
| WO-1999007693-A1 | BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007694-A1 | COMPOUNDS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
| US-5852193-A | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals | ELI LILLY AND COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0878474-A2 | Intermediates and a process for preparing benzo[b]thiophenes | ELI LILLY AND COMPANY (US) | 1998-11-18 | — | — | EP | disclosed |
| WO-1998048793-A1 | INTERMEDIATES AND PROCESSES FOR PREPARING BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998049156-A1 | PROCESSES FOR PREPARING BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998048787-A1 | INTERMEDIATES AND A PROCESS FOR PREPARING BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998048792-A1 | A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0875507-A1 | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0875507-A1 | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0875510-A1 | Process for preparing benzothiophenes | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662202-B2 | Synthesis of cephalosporin compounds | COASY, DDT, PEPD | IDO1 1309/4885AGXT 1561/4885CA1 4159/4885 |
| US-10414745-B2 | Phenol derivatives to treat cancer | RB1, TP53, NCOR1 | IDO1 3044/4885AGXT 1890/4885CA1 4413/4885 |
| US-20140371240-A1 | NOVEL INSECTICIDAL AROMATIC AMIDES | CHRM1, CHRM2, H1-3 | IDO1 323/4885AGXT 536/4885CA1 1288/4885 |
| US-20180185497-A1 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | STAT3, STAT1, STAT4 | IDO1 3927/4885AGXT 4138/4885CA1 2963/4885 |
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | IDO1 3919/4885AGXT 4848/4885CA1 4605/4885 |
| US-11634503-B2 | Antibody drug conjugates (ADC) that bind to 158P1D7 proteins | LGALS3BP, PABPC4, PA2G4 | IDO1 4255/4885AGXT 4479/4885CA1 3157/4885 |
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | IDO1 3931/4885AGXT 2665/4885CA1 2949/4885 |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | IDO1 4710/4885AGXT 2610/4885CA1 4702/4885 |
| US-20160256563-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | CD2BP2, IGSF11, EPB41L2 | IDO1 4501/4885AGXT 4572/4885CA1 3199/4885 |
| US-20140193337-A1 | 18F-SACCHARIDE-FOLATES | FOLR1, FOLR2, FOLH1 | IDO1 505/4885AGXT 922/4885CA1 267/4885 |
| US-20140066476-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | IDO1 3919/4885AGXT 4848/4885CA1 4605/4885 |
| US-20140275591-A1 | NOVEL COMPOUNDS | SGMS2, SGMS1, SMPD1 | IDO1 2353/4885AGXT 2253/4885CA1 1967/4885 |
| US-10301274-B2 | Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-YL)-3-aminopropan-2-ol | ERLIN1, ERLIN2, MAN1B1 | IDO1 4358/4885AGXT 1484/4885CA1 4080/4885 |
| US-20080281094-A1 | Regioselective Functionalisation and Protection of Spirolactams | PAICS, CTSL, GNE | IDO1 2355/4885AGXT 2104/4885CA1 812/4885 |
| US-20110059010-A1 | DUAL PHASE DRUG RELEASE SYSTEM | SUCNR1, SUCLA2, SUMO2 | IDO1 3654/4885AGXT 1519/4885CA1 1567/4885 |
| US-20230279476-A1 | NOVEL ACRYLATE DERIVATIVES AND USES THEREOF | DCLRE1A, ACR, PHAX | IDO1 4769/4885AGXT 1161/4885CA1 4326/4885 |
| US-20050261492-A1 | Regioselective hydroxylation, functionalisation and protection of spirolactams | POR, CYP51A1, CYP17A1 | IDO1 3043/4885AGXT 2696/4885CA1 4136/4885 |
| US-20180044298-A1 | NOVEL PYRAZOLYL DERIVATIVES AS PEST CONTROL AGENTS | PIR, PLPBP, PDXK | IDO1 455/4885AGXT 134/4885CA1 4276/4885 |
| US-20180170949-A1 | SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | COASY, MRPL21, CHLSN | IDO1 2543/4885AGXT 173/4885CA1 3666/4885 |
| US-20030232854-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ABCC1, ABCB11, ABCB1 | IDO1 4120/4885AGXT 633/4885CA1 1801/4885 |
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP11B1 | IDO1 398/4885AGXT 473/4885CA1 4668/4885 |
| US-20150152049-A1 | Materials And Methods Useful To Induce Vacuolization, Cell Death, Or A Combination Thereof | BECN1, BAD, BAX | IDO1 4337/4885AGXT 2911/4885CA1 2026/4885 |
| US-20130004455-A1 | POLY(ORGANOPHOSPHAZENE) COMPOSITION FOR BIOMATERIALS | PHOSPHO1, PGLS, PHYKPL | IDO1 1990/4885AGXT 858/4885CA1 954/4885 |
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, MRPS18A | IDO1 4403/4885AGXT 2352/4885CA1 2605/4885 |
| US-20030229132-A1 | Small molecule modulators of apoptosis | BAX, BCL2, BAD | IDO1 4257/4885AGXT 4733/4885CA1 3187/4885 |
| US-20180093982-A1 | METHODS AND USES OF COMPOUNDS FOR TREATING DISEASE | PKD1, PKD2, GLS | IDO1 2618/4885AGXT 359/4885CA1 2286/4885 |
| US-20200172523-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CYP4X1, CYP2B6, CYP2C19 | IDO1 1363/4885AGXT 1783/4885CA1 1979/4885 |
| US-20140213615-A1 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | BECN1, BAD, BAX | IDO1 4337/4885AGXT 2911/4885CA1 2026/4885 |
| US-20140288136-A1 | METHODS AND USES OF CYTOCHROME P450 INHIBITORS | CYP2B6, CYP2A6, CYP26B1 | IDO1 1058/4885AGXT 346/4885CA1 3456/4885 |
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | CD2BP2, DNPEP, LNPEP | IDO1 4077/4885AGXT 2170/4885CA1 1736/4885 |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | RNGTT, DUT, EMG1 | IDO1 2013/4885AGXT 443/4885CA1 1588/4885 |
| US-11564926-B2 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | THRB, TSHR, TRHR | IDO1 2360/4885AGXT 3951/4885CA1 4880/4885 |
| US-20160051694-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS | SIGLEC7, FUT7, SLC17A5 | IDO1 1801/4885AGXT 3157/4885CA1 2447/4885 |
| US-20120121517-A1 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF | PHOSPHO1, HSPA2, FEM1B | IDO1 2168/4885AGXT 3665/4885CA1 396/4885 |
| US-20160263243-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, CD2BP2, ADCK5 | IDO1 4446/4885AGXT 4624/4885CA1 3683/4885 |
| US-20150283255-A1 | CD19 BINDING AGENTS AND USES THEREOF | BCL6B, CD22, BCL6 | IDO1 1694/4885AGXT 4520/4885CA1 2412/4885 |
| US-20190233391-A1 | Benzodiazepine Derivatives As CCK2/Gastrin Receptor Antagonists | CCKBR, CCKAR, GRPR | IDO1 3959/4885AGXT 2285/4885CA1 802/4885 |
| US-11607460-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | IDO1 3931/4885AGXT 2665/4885CA1 2949/4885 |
| US-20100197951-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | TLR4, TLR3, TLR1 | IDO1 641/4885AGXT 3489/4885CA1 4529/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | IDO1 3919/4885AGXT 4848/4885CA1 4605/4885 |
| US-20130018103-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | IDO1 190/4885AGXT 2286/4885CA1 963/4885 |
| US-20170066735-A1 | Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-YL)-3-aminopropan-2-ol | ERLIN1, ERLIN2, MAN1B1 | IDO1 4358/4885AGXT 1484/4885CA1 4080/4885 |
| US-20140121186-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | EYA3, EYA2, PDE6C | IDO1 107/4885AGXT 1625/4885CA1 1967/4885 |
| US-20140274999-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CYP3A7, SEPTIN7, PEPD | IDO1 1791/4885AGXT 562/4885CA1 2585/4885 |
| US-20070037783-A1 | Migrastatin analogs and uses thereof | FOXM1, MTX1, C3AR1 | IDO1 3605/4885AGXT 3381/4885CA1 852/4885 |
| US-11986481-B2 | Method of synthesizing thyroid hormone analogs and polymorphs thereof | THRB, TSHR, TRHR | IDO1 2271/4885AGXT 3996/4885CA1 4881/4885 |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | IDO1 4710/4885AGXT 2610/4885CA1 4702/4885 |
| US-20170247363-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP1A2 | IDO1 293/4885AGXT 522/4885CA1 4632/4885 |
| US-20140234216-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | ALB, FOLR1, FOLR2 | IDO1 3349/4885AGXT 1410/4885CA1 2256/4885 |
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | MTOR, RICTOR, PIK3R5 | IDO1 3931/4885AGXT 2665/4885CA1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.